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SOMMARIO 
Background. Nel seme Human immunodeficiency virus (HIV)-1 e co-patogeni 
sono presenti in una complessa rete di citochine che influenza la replicazione 
locale e l’infettivita’ dei patogeni sessualmente trasmissibili, e, allo stesso tempo, è 
influenzata dalle infezioni del tratto genitale maschile (MGT). La comprensione di 
queste interazioni richiede un'analisi approfondita dei co-patogeni che infettano il 
MGT e delle citochine presenti nel liquido seminale, e delle relazioni intercorrenti 
tra questi e HIV-1. 
Metodi. La carica virale di 6 herpesvirus e HIV-1 e’ stata valutata nel plasma 
seminale e sanguigno di 83 soggetti HIV-1 infetti cronici non in terapia, e di 33 
soggetti non infetti mediante real-time PCR. Un saggio multiplex basato su beads è 
stato utilizzato per misurare i livelli di 21 citochine. I rapporti tra citochine sono stati 
definiti mediante il calcolo del coefficiente di correlazione di Spearman per tutte le 
possibili coppie di citochine. Blocchi di tessuto cervico-vaginale e linfoide umano 
sono stati inoculati con HIV-1 e trattati con interleuchina (IL)-7. La replicazione di 
varianti HIV-1 R5 o X4 è stata monitorata mediante misurazione della produzione 
dell’antigene p24gag. Cellule isolate da blocchi di tessuto al giorno 6 e 9 post-
infezione sono state caratterizzate per l'espressione dei marcatori CD3, CD4, CD8, 
e HIV-1 p24gag, e l’apoptosi è stata valutata misurando l'espressione delle 
proteine APO2.7 e Bcl-2 mediante citofluorimetria a flusso. 
Risultati. La maggioranza dei campioni di seme, ma non di sangue, dei soggetti 
HIV-1-infetti e’ risultata positiva per EBV e CMV (56% e 70%). Sangue e seme 
sono compartimenti immunologici separati e con l’infezione da HIV-1 il seme e’ il 
compartimento interessato dai maggiori cambiamenti nella composizione 
citochinica (16 vs 9 citochine alterate nel sangue). La riattivazione di CMV nel MGT 
è associata ad un aumento dei livelli delle citochine CCL5, CCL11 e CXCL9 nel 
seme. L’analisi dei rapporti tra citochine ha rivelato un numero maggiore di 
correlazioni e un aumento dell’intensita’ di correlazione per la maggior parte delle 
citochine sia nel seme che nel sangue dei soggetti HIV-1-infetti, rispetto ai non 
infetti. IL-7 e’ risultata essere una tra le citochine più concentrate nel seme e 
l’infezione da HIV-1 ne aumenta ulteriormente i livelli seminali. Abbiamo dunque 
utilizzato un sistema di infezione ex vivo di tessuti umani per studiare il ruolo di IL-7 
nella trasmissione di HIV-1. IL-7 e’ risultata promuovere la replicazione di varianti 
R5 e X4 di HIV-1 in modalita’ dose e tempo-dipendente. In blocchi di tessuto 
trattati con 25 ng/mL di IL-7 e’ stato osservato un numero maggiore di cellule T 
CD4+ infette e una riduzione della deplezione cellulare, rispetto a blocchi di tessuto 
non trattati con IL-7. Il trattamento con IL-7 e’ risultato inoltre in una riduzione della 
frazione di cellule T CD4+ infette esprimenti il marcatore apoptotico APO2.7 e in un 
aumento dei livelli di espressione del fattore anti-apoptotico Bcl-2. 
Conclusioni. HIV-1 è associato ad una alterazione generale dello spettro 
citochinico nel seme e alla riattivazione locale di CMV e EBV nel MGT, due 
fenomeni che sembrano essere correlati e potrebbero dunque influenzarsi 
reciprocamente. La ridotta flessibilita’ dei rapporti tra citochine potrebbe 
ulteriormente contribuire alla riattivazione di tali infezioni latenti. Tra le citochine nel 
seme, IL-7 esercita un effetto protettivo sulle cellule T CD4+ infette, favorendo lo 
stabilirisi di una infezione produttiva nel tratto genitale femminile. La comprensione 
di come il complesso di citochine, di concerto con i co-patogeni presenti nel seme, 
influenzano la trasmissione sessuale di HIV-1 sarà oggetto di ulteriori indagini. 
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ABSTRACT 
Background. In semen Human immunodeficiency virus (HIV)-1 and co-infecting 
pathogens are immersed in a complex network of cytokines that affects the 
replication and infectivity of sexually transmitted pathogens, and, at the same time, 
is affected by local infections in the male genital tract (MGT). Understanding the 
mechanisms of these interactions requires a comprehensive analysis of co-
infecting pathogens and cytokines in semen, and of the relations with HIV-1.  
Methods. Load of HIV-1 and 6 herpesviruses in semen and blood plasma of 83 
HIV-1 chronically infected individuals naïve to therapy and 33 HIV-uninfected 
individuals was evaluated by real-time PCR. A multiplex beads-based assay was 
used to measure the levels of 21 cytokines. The cytokine network was defined 
calculating the Spearman`s rank correlation coefficient for all pairwise 
combinations of cytokines. Human cervico-vaginal and lymphoid tissue blocks 
were inoculated with HIV-1 and treated with interleukin (IL)-7. Replication of R5 or 
X4 HIV-1 variants was monitored over a period of 12 days measuring HIV-1 p24gag 
antigen by a beads-based assay. Cells isolated from tissue blocks at day 6 and 9 
post-infection were characterized for the expression of the markers CD3, CD4, 
CD8, and HIV-1 p24gag antigen, and apoptosis was evaluated measuring the 
expression of the proteins APO2.7 and Bcl-2 by multicolor flow cytometry. 
Results. Epstein-Barr virus (EBV) and cytomegalovirus (CMV) DNA was found in 
semen of the majority of HIV-1-infecetd individuals (56% and 70%), but not in their 
blood. Blood and semen are separated immunological compartments, and with 
HIV-1 infection the major changes in cytokine composition occur in semen (16 vs 9 
cytokine levels altered in blood). CMV reactivation in the MGT was associated with 
increased levels of the cytokines CCL5, CCL11 and CXCL9. Analysis of the 
cytokines network revealed a higher number of correlations and increase in 
correlation strength for most of the cytokines in semen and blood of HIV-1-infected 
compared to HIV-uninfected individuals. Of note, interleukin (IL)-7 resulted to be 
one of the most concentrated cytokines in semen and HIV-1 infection further 
increased seminal IL-7. Thus we employed our system of human tissues ex vivo to 
study the effect of IL-7 on HIV-1 replication. IL-7 enhanced the replication of R5 
and X4 HIV-1 variants in dose and time-dependent manner. In tissue blocks 
treated with 25 ng/mL of IL-7 we observed higher number of HIV-1 infected CD4+ T 
cells and reduced CD4+ T cell depletion, compared with tissue blocks infected and 
maintained in the absence of IL-7. The fraction of HIV-1 infected CD4+ T cells 
expressing the apoptotic marker APO2.7 was reduced and the levels of the anti-
apoptotic factor Bcl-2 in infected cells were increased in the presence of IL-7.  
Conclusions. HIV-1 infection is associated with a general alteration of the cytokine 
spectrum in semen, and with the local reactivation of CMV and EBV in the MGT, 
two phenomena that appear to be related and may affect each other. The reduced 
flexibility of the cytokine network may favors the reactivation of such latent 
infections. Among seminal cytokines, IL-7 exerts a protective effect on HIV-1-
infected CD4+ T cells in the early stages of infection, preventing their death and 
thus promoting the establishment of a productive infection in the female genital 
tract. Understanding how other cytokines in concert with co-infecting pathogens 
found in semen affects HIV-1 sexual transmission will be object of further 
investigations. 
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1. INTRODUCTION 
1.1 The Human Immunodeficiency Virus 
1.1.1 Structure and genes of HIV 
The human immunodeficiency virus (HIV) is a Retrovirus belonging to the family of 
Lentivirus. HIV is the etiologic agent of the acquired immunodeficiency syndrome 
(AIDS) that results in extremely variable clinical outcomes, such as a severe 
immunodeficiency accompanied by the establishment of opportunistic infections 
and tumors, organ decay and central nervous system degeneration [1]. Two 
different HIV viruses exist: HIV-1, the pandemic type, and HIV-2, more represented 
in West Africa [2]. The clinical manifestations of HIV-1 and HIV-2 infection are 
similar, although their genome and antigenicity are different. The HIV virion is 
round shape with a diameter of about 100 nm. In the mature virion the viral 
genome is contained in a protein shield, called core, which is surrounded by a lipid 
bilayer, known as envelope (Fig. 1.1.1).  
 
 
Figure 1.1.1 Schematic illustration of the human immunodeficiency virus virion. 
(From http://arapaho.nsuok.edu). 
 
1.1.1.1 Genome 
The HIV genome consists in two identical positive-sense single stranded RNA 
(ssRNA+) molecules, each 9.2 Kbasis in lenght. HIV-1 genome comprises three 
essential genes gag, pol and env and the regulatory genes tat, rev, vif, nef, vpr and 
vpu (Fig. 1.1.2). HIV-2 genome organization is identical, but vpu that was replaced 
by vpx [3]. The genetic information is highly organized in the HIV genome: different 
genes use common sequences that are differently read by the RNA polymerase. 
Moreover, the genes tat and rev comprise sequences dispersed into the genome 
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that require an alternative splicing event to form a coding transcript [4]. At each end 
of the ssRNA molecule there is a sequence called Long Terminal Repeat (LTR) 
that mediates the integration of HIV genome into the genome of a host cell and 
regulates viral replication. The LTRs contain promoters and enhancers of gene 
transcription specific for host transcription factors such as Nuclear Factor kappa B 
(NF-kB), activator protein 1 (AP1), nuclear factor of activated T cells (NFAT), as 
well as virus-encoded factors [4].   
 
 
 
1.1.2 Organization of the HIV-1 genome. (From http://www.stanford.edu).  
 
1.1.1.2 Core 
The core of HIV is a nucleocapsid made of an elongated conical shell with 
icosahedral symmetry composed of proteins of 24 kDa in weight, called p24, which 
contains the HIV genome. The nucleocapsid is surrounded by a spherical shell, 
known as matrix, made of proteins of 17 kDa, called p17, anchored to the viral 
envelope through a myristic acid residue. The two ssRNA+ molecules in the capsid 
are associated with two proteins of 7 and 9 kDa, called p7 and p9 respectively, that 
function as packaging proteins. The proteins p7, p9, p17 and p24 are encoded by 
the gene gag, which transcript is translated in a poly-protein of 55 kDa, called p55 
that is then cleaved by viral proteases in the above mentioned components during 
virion maturation [5]. In addition to the ribonucleoproteic complex, the core contains 
several virus-encoded enzymes: the reverse transcriptase (RT), a heterodimer 
constituted of two proteins of 66 and 51 kDa, the integrase, called p32, that 
facilitates the insertion of HIV genome into the host genome, and the protease, a 
homodimer composed of a protein of 10 kDa. These enzymes are encoded by the 
gene pol, which transcript is translated into a poly-protein of 180 kDa, called Gag-
Pol, that is then cleaved by the viral potease itself [6]. The core also contains 
molecules that are important for the early stages of the biologic cycle of HIV and 
accessory proteins. Some of these proteins are virus-encoded such as Trans-
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activator of transcription (Tat or p14), Regulator of virion expression (Rev or p19), 
Negative regulatory factor (Nef or p27), Viral infectivity factor (Vif or p23), Viral 
protein U (vpu or p16) and Viral protein R (Vpr or p15) (or Viral protein X in case of 
HIV-2), and some derive from the host cell, such as cyclophilin A and a tRNAlys that 
serves as primer for the RT to initiate HIV genome reverse transcription [7]. 
1.1.1.3 Envelope 
The HIV envelope is a phospholypid bilayer acquired from the host cell during 
virion budding and release. The envelope contains host-derived proteins, including 
Human leukocyte antigens (HLAs) and adhesion molecules, and a series of spikes 
of 9-10 nm in length, called Env. Each spike is a trimeric complex of a glycoprotein 
of 120 kDa, called gp120, that from a cap non-covalently bound to a stem of a 
trimeric complex of transmembrane glycoprotein of 41 kDa, called gp41. The env 
gene encodes a protein called gp160 that, after glycosilation in the Golgi 
apparatus, is cleaved into gp120 and gp41. Respectively, these proteins enable 
HIV to attach to and fuse with the target cell membrane [8, 9]. 
1.1.2 Replication cycle of HIV-1 
The replication cycle of HIV-1 begins with a high affinity binding between gp120 
and the receptor CD4 expressed on the target cell surface. CD4 is a protein mainly 
expressed by lymphocytes with ‘helper-inducer’ activity, also known as CD4 T 
cells, that use CD4 as co-receptor for recognizing the antigen-HLA complex on the 
surface of an antigen presenting cell. CD4 is also expressed by monocytes and 
macrophages, dendritic cells, Langerhans cells, and some hematopoietic 
progenitors circulating in the blood stream and resident in the bone marrow. The 
interaction CD4-gp120 induces a conformational change in the structure of gp120 
that leads to the exposure of the binding site for another receptor, called co-
receptor, which presence on the host cell surface is required for viral entry. There 
are two main receptors which HIV-1 gp120 recognizes: CXC-chemokine receptor 
(CXCR) 4, that binds the chemokines stromal cell-derived factor (SDF)-1α 
(CXCL12a) and SDF-1β (CXCL12b); CC-chemokine receptor (CCR) 5, that binds 
the chemokines, also known as β-chemokines, macrophage inflammatory protein 
(MIP)-1α (CCL3), MIP-1β (CCL4), and regulated on activation normally T-cell 
expressed and secreted (RANTES, CCL5). The HIV-1 variants that bind to CXCR4 
or CCR5 are called X4- or T-tropic, and R5- or macrophage (M)-tropic respectively 
[10, 11]. In addition to these two receptors, it was demonstrated that the receptors 
that HIV-1 can use to enter a target cell are more than seven. Mutations in the 
aminoacidic sequence of gp120 may modify the tropism of the virus: is some HIV-
1-infected patients a progressive evolution from R5-tropic viruses, associated to 
transmission and acute infection, to X4-tropic viruses during late stages of the 
disease has been reported [12]. The interaction between gp120 and the co-
receptor induces the exposure and activation of the lypophlic N-terminal region of 
gp41, called fusion peptide, that mediates the fusion of the viral envelope with the 
plasma membrane of a target cell [13]. Upon HIV-1 entry into the target cell, the 
core dissolves and a reverse-transcription complex (RTC) assembles in the 
cytoplasm. The RTC, comprising p17, viral enzymes, genomic RNA, and factors of 
cellular origin, allows the reverse transcription of the two identical molecules of 
ssRNA+ in double stranded DNA. HIV-1 RT lacks proof-reading activity and this 
results in a high rate of mutation that allows the virus to evade the host immune 
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defenses since the early stages of infection. The RTC then evolves in pre-
integration complex (PIC) that crosses the nuclear membrane [14]. Inside the 
nucleus, the HIV-1 integrase promotes the insertion of the viral DNA in the host cell 
genome. At this stage the virus is called provirus and it can persist in a status of 
transcriptional latency for long periods of time [15]. The transcriptional status of the 
provirus largely depends on the metabolic status of the host cell [16, 17]. Antigenic 
stimulation through activation of the T-cell receptor signaling or stimulation of the 
host cell by pro-inflammatory cytokines can lead to activation and nuclear 
translocation of host transcription factors, such as NF-kB, that turn to activate or 
enhance HIV-1 provirus transcription [18]. This and other factors, including co-
infecting pathogens, can break latency and initiate HIV-1 transcription, thus 
affecting progression to AIDS. The transcription of proviral genes is operated by 
the host enzyme RNA polymerase II, starting from the LTR at the 5’ of the provirus. 
This sequence contains the promoter and the binding site for activators and 
regulators of transcription. Initially, the RNA polymerase is extremely inefficient in 
transcribing the proviral genes and most of the times transcription is terminated 
100 basis from the promoter, when the nascent strand of RNA forms a stem-and-
loop structure and the enzymes detaches from it [19]. When a complete transcript 
is produced, it translocates to the cytoplasm where the synthesis of the proteins 
Tat, Rev and Nef occurs. 
Tat binds to the 5’LTR enhancing the efficiency of the RNA polymerase, preventing 
the premature termination of the transcription of HIV-1 genes [20]. 
Rev inhibits the host RNA splicing machinery thus controlling the nuclear export of 
intron-containing HIV-1 RNA. Depending on the amount of Rev in the nucleus, the 
production of HIV-1 components can switch from regulatory and accessory protein 
to structural proteins, and the unspliced HIV-1 genome can enter the cytoplasm to 
be incorporated into new virions [21]. 
Nef performs a striking number of activities that cooperate to delay the elimination 
of HIV-1-infected cells by the immune system to turn them into more effective 
producers of fully infectious virions. Of note, Nef down-regulates the expression of 
the CD4 and HLA molecules on the surface of the infected cells, by recruiting these 
receptors to the endocytic machinery or by rerouting them to lysosomes for 
degradation [22, 23]. These Nef functions protect virally infected T cells against 
cytotoxic T lymphocyte (CTL) lysis, reduce their migration in response to the 
chemokines CXCL12a and CXCL12b, prevent superinfection, and may facilitate 
the release of infectious virions.  
Vpr is a virion-associated factor which reported activities include activation of 
proviral transcription, cell-cycle arrest in the G2 phase, induction of cell death, and 
enhancement of the fidelity of reverse transcription [24, 25]. Vpu is produced 
together with Env during the late stage of the viral life cycle. Vpu interacts with 
newly synthesized CD4 in the endoplasmatic reticulum and recruits an ubiquitin 
ligase complex to its cytoplasmic tail to mediate polyubiquitinylation and 
proteasomal degradation [26, 27]. CD4 degradation may facilitate virus release, 
avert superinfection, and enhance the incorporation of functional Env proteins into 
progeny virions by preventing the formation of gp120/CD4 complexes in virally 
infected cells. Vif is a factor essential for viral replication in primary T cells and in 
vivo. Its role is to disrupt the antiviral activity of the human enzyme APOBEC3G by 
targeting it for ubiquitination and cellular degradation. In the absence of Vif, 
APOBEC3G is incorporated into HIV-1 virions, inhibits viral DNA synthesis during 
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reverse transcription, and catalyzes deamination of cytidine to uridine during 
negative-strand DNA synthesis [28]. These changes lead to the degradation of the 
viral DNA and/or become fixed as guanosin-to-adenosin transitions in the proviral 
sequences (known as G-to-A hypermutations). 
The final step of the viral replication cycle occurs on the plasma membrane of the 
host cell. The Env polyprotein (gp160) is cleaved in the Golgi by the HIV-1 
protease and processed in the two envelope glycoproteins gp41 and gp120. Once 
they are transported to the plasma membrane of the host cell, gp41 anchors gp120 
to the plasma membrane. The Gag (p55) and Gag-Pol (p160) polyproteins also 
associate with the inner surface of the plasma membrane, along with the HIV-1 
genomic ssRNA+ as the forming virion begins to bud from the host cell. At this 
stage the HIV-1 accessory proteins and some host factors, such as cyclophilin A 
and tRNAlys, are incorporated in the budding virus. Finally, the cleavage of the 
polyproteins Gag (p55) and Gag-Pol (p160) produces the enzymes necessary for 
the next round of infection, and the structural components p7, p17 and p24 that 
assemble to produce a mature virion [29].  
 
 
Fig 1.1.3 Replication cycle of HIV. (From http://www.niaid.nih.gov). 
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1.1.3 Pathogenesis of HIV-1 infection 
The pathogenesis of HIV-1 infection begins as an acute infection that after a long 
period of latency, which can last 3 to 20 years, leads to a severe status of 
immunodeficiency, called acquired immunodeficiency syndrome (AIDS) [30]. The 
major determinant of the pathogenesis and disease caused by HIV-1 is the virus 
tropism for CD4+ T cells, which results in a reduction in the number of these cells 
and consequent abolition of the helper function of adaptive immunity. HIV-1 
induces several cytopathologic effects that may kill the infected T cell. In the the 
acute phase of infection, HIV-induced cell lysis and killing of infected cells by CTLs 
account for CD4+ T cell depletion, although apoptosis may also be an important 
factor [31]. During the chronic phase, the consequences of generalized immune 
activation, coupled with the gradual loss of the ability of the immune system to 
generate new T cells, account for the slow decline in CD4+ T cell number [32, 33]. 
The course of HIV disease parallels the reduction in CD4+ T cell numbers and the 
amount of virus in the blood (Fig. 1.1.4).  
 
 
 
Figure 1.1.4 Time course and stages of HIV disease.  
(From Murray et al., 2008 [34]). 
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During the acute phase, there is a large burst of virus production and infection 
spread systemically, in particular to secondary lymphoid organs. T cell proliferation 
and responses to the infected lymphoid and myeloid cells promotes a 
mononucleosis-like syndrome. The CD8+ T cell response is thought to be important 
in controlling virus levels, which peak and then decline, as the CD4+ T cell counts 
recover. Virus levels in the blood decrease during a clinically latent period, but viral 
replication continues in the secondary lymphoid organs [35]. At the same time, 
virus can remain latent in macrophages, dendritic cells and resting T cells, 
establishing reservoirs in many organs. Continuous HIV-1 replication results in a 
state of generalized immune activation persisting throughout the chronic phase 
[32]. Immune activation, which is reflected by the increased activation state of 
immune cells and release of pro-inflammatory cytokines, results from the activity of 
several HIV-1 gene products and the immune response to ongoing HIV-1 and co-
infecting pathogen replication. Immune activation has also been linked to the 
breakdown of the defenses of the gastrointestinal mucosal barrier caused by the 
depletion of mucosal CD4+ T cells during the acute phase of disease [36, 37]. 
Late in the disease, virus levels in the blood increase, CD4+ levels are significantly 
decreased, CD8+ levels also decrease, X4-tropic virus rises (in about 50% of the 
infected individuals), the structure of the lymph nodes is destroyed [38], and the 
patient becomes immunosuppressed (Fig 1.1.4). Stage IV or AIDS, as defined by 
the World Health Organization, is characterized by severe symptoms which 
includes toxoplasmosis of the brain, candidiasis of the esophagus, trachea, bronchi 
or lungs and Kaposi's sarcoma, and a CD4+ T cell count of less than 200/µL [39].  
The central role of the CD4+ helper T cells in the initiation of an adaptive immune 
response is indicated by the extent of the loss of function caused by HIV-1 
infection. When CD4+ T cells are unavailable or not functional, antigen-specific 
immune responses (especially cellular immune responses) are incapacitated, and 
humoral responses are uncontrolled. The loss of the CD4+ T cells responsible for 
activating macrophages allows the outgrowth of many of the opportunistic 
intracellular infections characteristic of AIDS (e.g., fungi and intracellular bacteria). 
Of importance, the decrease in number and the inability to activate CD8+ T cells 
increases the potential for recurrence of latent viruses, including JC polyomavirus 
progressive multifocal leukoencephalopathy (PML), herpes simplex virus, and 
cytomegalovirus infections, and even Epstein-Barr-associated lymphomas and 
human herpesvirus-8-associated Kaposi sarcoma [34].  
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1.2 AIDS epidemic and HIV transmission 
After 30 years of epidemic the persons living with HIV are about 33.3 million 
worldwide [40]. The implement of preventive strategies and better access to 
therapeutic treatment, especially in low- and middle-income countries, led to 
decreased number of AIDS-related deaths and of new infections. Although the 
number of new infections has been constantly decreasing since the mid nineties, in 
2009 there were still an estimated 2.6 million people newly infected with HIV (Fig. 
1.2.1), among them 1.8 million in sub-Saharan Africa, which, with an estimated 
22.5 million people living with HIV in 2009, remains the largest epidemic in the 
world (Fig. 1.2.2).  
HIV-1 is the dominant HIV type worldwide, while HIV-2 is less infectious and 
aggressive virus, although it can cause AIDS as well as HIV-1, and remains 
restricted to West Africa [2]. For these reasons most of the studies, comprising 
ours, focused on HIV-1. 
	  
Figure 1.2.1 Number of peolple newly infected with HIV. (From UNAIDS 2010 [40]).	  
	  	  
Figure 1.2.2 Global prevalence of HIV, 2009. (From UNAIDS 2010 [40]). 
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1.2.1 Routes of HIV-1 transmission 
The major routes of HIV-1 transmission are mucosal exposure to infected body 
fluids such as blood, semen, vaginal fluids or breast milk, parenteral inoculation 
using infected needles or medical devices, and intrauterine mother-to-child 
transmission (Table 1.2.1). Despite the probability of HIV-1 sexual transmission is 
generally low, HIV-1 is primarily a sexually transmitted virus: about 80% of HIV-1-
positive adults became infected through unprotected sexual intercourse [41]. In fact 
there are many factors that affect the efficiency of HIV-1 sexual transmission, first 
the anatomical site of infection. Unprotected receptive anal intercourse is 
associated with the higher risk of HIV transmission among all sexual practices, due 
to the thin monolayer of epithelial cells of the mucosa of the lower intestinal tract, 
which is highly susceptible of disruption during sexual intercourse and thus 
represents a weak barrier against HIV-1 breakthrough. Although this route of 
transmission accounts for the majority of new cases in high-income countries it is 
responsible for a small fraction of new cases globally. The penile and cervico-
vaginal mucosa are mostly covered by stratified squamous epithelium that offers a 
better mechanical protection against HIV-1 entry. Indeed the efficiency of HIV-1 
transmission via vaginal intercourse is 10 times lower than receptive anal 
intercourse (Table 1.2.1). Although its low efficiency, male-to-female HIV-1 
transmission via unprotected vaginal intercourse accounts for the majority of all 
transmission events, more than the number of newly infected men due to exposure 
to cervico-vaginal fluids harboring HIV-1. 
Slightly more than half of all people living with HIV are women and in sub-Saharan 
Africa young women are as much as eight times more likely than men to be HIV 
positive [40]. Understanding the mechanisms of semen-mediated HIV-1 
transmission to the female genital mucosa is pivotal for the development of 
effective preventive strategies aimed to slow down the major driver of the 
pandemic spread of the virus. 
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HIV 
invasion 
site 
Sub-
location 
Type of 
epithelium 
Transmission 
medium 
Transm. 
prob. per 
exposure 
event 
Estimated 
HIV cases 
worldwide  
Female 
genital 
tract 
Vagina 
Squamous, 
non-
keratinized 
Semen 1 in 200 -1 in 2,000 
12.6 
million 
Ecto-
cervix 
Squamous, 
non-
keratinized 
Endo-
cervix 
Columnar, 
single layer 
Other Various 
Male 
genital 
tract 
Inner 
foreskin 
Squamous, 
poorly 
keratinized 
Cervicovaginal 
and rectal 
secretions and 
desquamations 
  
1 in 700 - 
1 in 3,000 
10.2 
million‡ Penile 
urethra 
Columnar, 
stratified 
Other Various 
Intestinal 
tract 
Rectum Columnar, single layer Semen 
1 in 20 -  
1 in 300 3.9 million
§ 
Upper GI 
tract Various Semen 1 in 2,500 1.5 million 
    
Maternal 
blood, genital 
secretions 
(intrapartum) 
1 in 5 -    
1 in 10 960,000 
    Breast milk 1 in 5 -    1 in 10 960,000 
Placenta Chorionic villi 
Two layer 
epithelium 
(cyto- and 
syncytio-
trophoblast) 
Maternal blood 
(intrauterine) 
1 in 10 -  
1 in 20 480,000 
Blood 
stream     
Blood 
products, 
sharps 
95 in 100 
- 1 in 150 
2.6 
million
 
 
Table 1.2.1 Contribution of HIV invasion sites to global HIV infections.  
‡Includes men having sex with men (MSM), bisexual men and heterosexual men.  
§Includes MSM, bisexual men and women infected via anal receptive intercourse. 
(Adapted from Hladik & McElrath, 2008 [42]). 
	  	   11	   	  
	  
1.3 Semen  
Semen is by classic definition the survival medium for spermatozoa, which main 
function is to protect and deliver sperm to the female genital tract (FGT). Semen 
also contains many molecules that actively signal in the FGT and modulate the 
local immune response to induce favorable conditions for fertilization and 
establishment of pregnancy. In addition to its reproductive tasks, semen serves as 
vector for pathogens originating from local infections in the male genital tract, 
which may modify the characteristics and immunologic properties of semen, thus 
affecting the transmissibility of pathogens themselves. Therefore, investigating the 
interplay between HIV-1, co-infecting pathogens and immunologic factors in semen 
is essential for a better understanding of HIV-1 sexual transmission and ultimately 
for the development of effective preventive strategies.  
1.3.1 Origin and composition  
Semen is a fluid composed of cells and secretions from the testes, epididymis, 
prostate, seminal vesicles and bulbourethral glands (Fig. 1.3.1).  
 
 
Figure 1.3.1 Schematic anatomy of the male urogenital tract.  
(From http://nursingcrib.com). 
 
The testis is the organ where androgens and spermatozoa are produced and it is in 
continuity with its extra-testicular pathways, comprising the epididymis, that 
transmit sperm to the urethra. Sperm make up only a small fraction, 1 to 5%, of 
whole semen. The prostate, seminal vesicles and bulbourethral glands are 
accessory glands, which secretions constitute the seminal plasma [43]. In fertile 
men, the sequence in which the accessory glands contribute their secretions to the 
ejaculate is fixed: the bulbourethral glands secrete a thin, mucoid, alkaline solution 
containing glycoproteins to neutralize the urinary tract and lubricate the tract during 
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the excitatory stage of sexual response. The bulbourethral glands contribute only a 
minimal amount to the ejaculate, less than 1%. Then, the prostate, epididymis and 
ducti deferentia contract together, discharging spermatozoa and prostatic 
secretions. The prostate secretion represents about 30% of the ejaculate volume, 
in the form of a slightly opaque fluid containing zinc, acid phosphatase, prostate-
specific antigen, citric acid and proteolytic enzymes. Finally the seminal vesicles 
contract and expel the pellet of spermatozoa to the outside with their secretions, 
which are an alkaline, yellowish, viscid fluid that constitutes 60-70% of the 
ejaculate volume. Fructose and a variety of prostaglandis appear to be produced 
specifically by the seminal vesicles.  
1.3.2 Physical and chemical characteristics  
1.3.2.1 pH and buffering capacity 
Semen has a very high buffering capacity and maintains its pH near neutral in the 
acidic vaginal environment, providing the sperm with the opportunity to enter the 
cervical mucus. On the basis of different reports, semen pH ranges between 7.4 
and 8.4. The measured pH can depend on the length of time since ejaculation, and 
it tends to increase shortly after ejaculation as a result of loss of CO2. Further aging 
of whole semen can result in a substantial decrease in pH resulting from fructolysis 
and the production of lactic acid.	  It has been calculated that HCO3/CO2 contributes 
24.9%, protein contributes 28.5%, and low–molecular weight components such as 
citrate, inorganic phosphate, and pyruvate contribute half to the buffering capacity 
of semen [44].	  
1.3.2.2 Osmolarity 
Semen is notable for its high osmolarity, which is substantially higher than that of 
blood plasma. The osmolarity of semen depends greatly on the concentration of 
sugars and other organics concentrations as well as ionic salt concentrations. 
Some researchers have noted that osmolarity increases measurably with semen 
aging [45].  
1.3.2.2.1 Ions 
Citrate is one of the most important anions present in human semen. Although 
citrate has high affinity for calcium, magnesium, and zinc, the citrate concentration 
is more than double the divalent metal concentration, consequently much of the 
seminal citrate is strongly anionically charged. The calcium concentration in semen 
is of great interest as a result of its relation to sperm motility, metabolism, the 
acrosome reaction, and fertilization itself. The other important ions found in human 
semen are magnesium, potassium, sodium and zinc. The concentrations of 
calcium, magnesium, and zinc are highly correlated. Magnesium and zinc are also 
found complexed with other molecules, which can sometimes be bound to the 
surface of the sperm cells [46]. Zinc is excreted from the prostate as a low-
molecular weight complex with citrate. After ejaculation, 50% is redistributed and 
bound to medium- and high-molecular weight compounds from the seminal 
vesicles [45]. 
1.3.2.2.2 Fructose and glucose	  
Fructose is an important source of energy for the sperm and measurements of 
fructose concentration in whole semen can change over time as a result of 
fructolysis, the primary source of lactic acid in semen. Fructose is also likely 
involved in protein complexes, particularly in coagulated semen. Glucose may also 
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be an important source of energy to spermatozoa  and is present in substantial 
concentrations. It should be noted that the variation in the measured values among 
studies is very large (range of 136–628 mg/100 mL for fructose, range of 4–300 
mg/100 mL for glucose) [45].  
1.3.2.2.3 Proteins 
The bulk of the proteins found in semen derive from the seminal vesicles, although 
albumin is mainly of prostatic origin [46]. Albumin makes up about one third of the 
protein content of semen, the average albumin concentration is 1550 mg/100 mL 
and the average total protein concentration is 5040 mg/100 mL. The amino acid 
content of semen is much higher than that of plasma, and it increases rapidly 
(particularly glutamic acid) in the hours following ejaculation. 
1.3.2.3 Viscosity 
The rheological properties of semen change dramatically after ejaculation; the 
initial ejaculate quickly coagulates into a gelatinous material, and this material then 
liquefies. The coagulation factors derive from the seminal vesicles, while liquefying 
factors come from the prostate [47]. The relative contribution to sperm and seminal 
plasma to the viscosity of semen has not been clearly defined. Differences still 
exist as to what can be regarded as normal sperm concentration and many 
different cut-off values have been proposed, including 60, 20 and 10 millions of 
spermatozoa per mL [43] in a total average volume of 3.4 mL [45]. 
1.3.3 Immunological characteristics  
1.3.3.1 Mechanisms of defense 
Seminal plasma has strong bacteriostatic and bactericidal effects thanks to the 
presence of a variety of innate immune defense mediators including zinc, 
lysozyme, transferrin, and transglutaminase (Fig. 1.3.2) [48]. Studies of the gut and 
FGT immunologic milieus have begun to define the role of epithelial cell products 
such as chemokines, cytokines, mucins, and defensins in mucosal defense (see 
section 1.4.2.2), but there are few comparable published studies on immune 
defense mechanisms of male genital tract. The data produced to date indicate that 
epithelial cells in the male genital tract are capable of secreting antimicrobial 
peptides [49-51]. Furthermore, data are accumulating that innate defense 
mechanisms including defensins and cytokines are up-regulated in the male genital 
tract by infection [52]. β-chemokines (CCL3, CCL4, CCL5) are often detectable in 
semen from HIV-1-infected men [53]. Immunoglobulin (Ig) concentrations in normal 
human semen are much lower (∼1-10%) than those in blood [54]. Both IgG and IgA 
isotypes are present in semen, but IgG predominates (total IgA = 9584 ng/mL vs. 
total IgG = 29741 ng/mL [55]). IgG and IgA are synthesized by plasma cells 
associated with the glands of Litre in the penile urethra [Pudney, 1995 #354], but 
much of the Ig in semen is apparently a transudate from the blood compartment 
[54]. The IgA found in mucosal secretions (sIgA) is different from serum IgA. It is 
composed of 10-S dimer and a J chain. The J chain is made by plasma cells and 
joins 7-sIgA monomers (the IgA normally found in serum) into 10-S dimers (and 
IgM monomers in pentameric sructures). A polymeric Ig receptor (p-IgR), primarily 
expressed in the genital tract by columnar epithelial cells in the penile urethra, 
binds polymeric IgA and IgM and transports it through the cell to the luminal 
mucosal surface [56]. Although sIgA are able to agglutinate bacteria, they do not 
have innate bactericidal activity. However, they can synergize with lysozyme and 
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complement to enhance antibacterial defense [57]. It was reported that IgA 
concentrations positively correlated with the seminal PMN count, suggesting that 
IgA concentrations are elevated in the male genital tract during episodes of genital 
tract inflammation and/or infection [55, 58].  
 
 
Figure 1.3.2 Mechanisms of innate defense in the male genital tract and in semen. 
(From Mucosal Immunology, 2005 [59]). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   15	   	  
	  
1.3.3.2 Cytokines 
Semen is rich in several cytokines which biological significance is still poorly 
understood. Table 1.3.1 reports the results of one of the most comprehensive 
studies of semen from healthy fertile men, conducted by Politch at al. [55]. The 
men enrolled in the current study were at low risk for STIs and subfertility. 
Variables that could affect levels of cytokines and other immunologic factors in 
semen from different ethnic and demographic groups include genetic 
polymorphisms, differences in diet, hygiene, sexual practices and drug use. In 
addition, genital flora and sexually transmitted infections can influence seminal 
cytokine and antibody levels [60].  
 
Cytokine n % positive Median (pg/mL) 
Range 
(pg/mL) 
IL-1α 81 68 6.0 ND-214.0 
IL-1β 83 54 2.0 ND-118.0 
IL-2 77 1 ND ND-24.0 
IL-5 19 100 31.3 11.0-227.0 
IL-6 79 99 6.0 ND-110.0 
IL-7 19 100 2532.0 1109.0-3985.0 
IL-10 80 9 ND ND-32.0 
IL-12 80 13 ND ND-18.0 
IL-13 19 53 3.1 ND-149.3 
IL-17 19 74 11.6 ND-84.9 
TNF-α 59 20 ND ND-40.3 
IFN-γ 82 37 ND ND-130.0 
IFN-α 60 55 3.3 ND-270.8 
TGF-β1 (total) 77 100 85120.0 37520.0-192640.0 
TGF-β1 (latent) 63 100 80118.0 36840.0-190230.0 
TGF-β1 (active) 75 100 1096.0 168.0-9214.0 
G-CSF 60 87 64.7 ND-5262.6 
GM-CSF 60 7 ND ND-1190.6 
CXCL8 82 100 1305.0 384.0-14712.0 
CCL3 82 15 ND ND-136.0 
CCL4 83 81 66.0 ND-1050.0 
CCL5 83 98 126.0 ND-1480.0 
CXCL12a 59 98 5741.9 ND-17955.4 
CCL2 60 100 2980.9 292.4-81516.1 
 
Table 1.3.1 Concentration of cytokines in semen of ‘n’ healthy fertile men.  
ND = non detectable. (Adapted from Politch et al., 2007 [55]). 
 
1.3.3.2.1 Transforming growth factor-β 
Transforming growth factor (TGF)-β is the highest cytokine in concentration 
present in human seminal plasma. Seminal plasma contains more active TGF-β 
than do other body fluids including blood plasma and breast milk [61]. In addition, 
seminal plasma contains a large amount of latent (inactive) TGF-β that can be 
	  	   16	   	  
	  
converted to the active form to achieve a sustained biologic effect. Indeed, TGF-β 
is thought to be synthesized in latent (inactive) form primarily in the prostate; 
following ejaculation, seminal TGF-β may be converted to its active form in the 
female tract by the acidic vaginal pH, or enzymes found in seminal plasma or 
vaginal secretions [62]. TGF-β is a key regulator of several aspects of the immune 
response (see section 1.3.4) and its role in HIV-1 transmission is controversial. 
1.3.3.2.2 Interleukin-7 
IL-7 is a member of the common gamma-chain cytokine family comprising IL-2, IL-
4, IL-15, and IL-21 [63]. IL-7 plays a major role in modulating T cell development, 
and peripheral naïve and memory T cell homeostasis [64-66]. The main source of 
IL-7 in semen is believed to be the prostate, where IL-7 is important for maintaining 
T cells residing in prostate-associated lymphoid tissue [67]. Politch et al. were the 
first to report the presence of IL-7 in semen, at an average concentration of 2500 
pg/mL, speculating that this cytokine plays a role in the maintenance of 
intraepithelial CD8+ T cells in the male genital tract [55]. A potential role of IL-7 
during fertilization, and the effects of such an amount of IL-7 on the leukocytes 
resident in the female genital mucosa (FGM) remain to be investigated. 
1.3.3.2.3 Chemokines  
The three chemokines CXCL8, CXCL12a and CCL2 are present in semen at high 
concentration. CXCL12a is involved in the guidance, colonization, survival and 
proliferation of mammalian primordial germ cells, the progenitors of spermatozoa 
and oocytes [68]. Thus, it is also possible that CXCL12a may have a key role in the 
maintenance of male fertility. Although the function of CXCL8 and CCL2 in the 
male genital tract is not clear, these chemokines are thought to be involved in the 
inflammatory reaction that occurs in FGM after coitum (see section 1.3.4). 
Moderate levels of CCL4 and CCL5 were detected in semen. The β-chemokines 
CCL3, CCL4 and CCL5, and the chemokines CXCL12a and CXCL12b have been 
shown to inhibit HIV-1 entry into target cells by competing for the binding to the co-
receptors CCR5 and CXCR4 respectively [69]. However, these chemokines may 
contribute to the recruitment of immune cells to the genital submucosa (i.e. CD4+ T 
cells by CXCL12a, both lymphocytes and macrophages by β-chemokines), which 
can be observed upon semen deposition onto the FGM. Thus, despite they can 
display anti-HIV-1 activity, their presence is semen may result in more target cells 
available for HIV-1 to infect during transmission.  
1.3.3.2.4 Other cytokines 
Prominent cytokines associated with T cell function, including IL-2, IL-10, IL-12 and 
IFN-γ, have been detected at elevated concentrations in semen of men with genital 
infections [70], while cellular immune activity is low in the genital tract of healthy 
men. Moderately high IL-5 concentration is present semen. This cytokine promotes 
the development of B cells and the production of IgA [71], and may play a role in 
humoral immune defense of the male genital tract.  
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1.3.4 Immuno-regulatory effects of semen on the FGT 
In the vast majority of mammals, comprising humans, ejaculated spermatozoa are 
deposited in the vagina and have to reach the fallopian tubes to fertilize the egg at 
this location. Coagulation of semen occurs as a result of interaction of components 
of the prostate and a protein from the seminal vesicles (seminogelin), possibly to 
enhance the retention of semen in the vaginal canal. After 15-30 minutes, 
proteolytic enzymes contained in the prostatic secretions dissolve the seminal 
coaugulum (liquefaction), allowing spermatozoa to leave the seminal compartment 
and penetrate the cervix [43]. Although the great importance of semen as 
transporter and survival medium for spermatozoa, seminal fluid also contains 
signaling molecules that affect FGM immunity, thus promoting receptivity for 
embryo implantation. Cytokines, prostaglandins and other bioactive molecules 
present in semen initiate these events by interacting with the epithelial lining of the 
FGM triggering gene expression, leukocyte recruitment and activation of the innate 
and adaptive immunity in a sequence that resembles a classical inflammatory 
cascade [61].  
The most immediate and evident effect of semen deposition onto the FGM is local 
induction of the secretion of pro-inflammatory cytokines, accompanied by a 
dramatic influx of inflammatory cells. These events were extensively described in 
mice and other mammals, while in humans the immune response to seminal fluid 
have received little attention. Leukocytosis was observed in samples recovered 
from the cervix of women artificially inseminated using a cervical brush, without 
providing any indication of the cellular changes within the genital mucosa [72, 73]. 
Seminal plasma, as opposed to sperm, mediates these events, since 
vasectomized mice, but not mice from which seminal vesicles have been surgically 
removed, elicit such response [74]. Recently, a study conducted by Sharkey et al. 
compared the composition of the leukocyte population, and the cytokine gene 
expression profile in cells recovered from needle biopsies from the ectocervix of 
ovulating women before and after vaginal intercourse, with or without coitus [75]. 
Macrophages and CD1a+ dendritic cells are among the major leukocyte 
populations recruited into the FGM after semen deposition. These cells are 
professional antigen-presenting cells and, in concert with cytokines, may play an 
important function in the induction of immune tolerance to male transplantation 
antigens contained within the ejaculate, as shown in mice [76]. Macrophages are 
also involved in tissue remodeling to facilitate implantation and placental 
development, because they produce matrix metalloproteinases (MMPs) under the 
influence of cytokines, extracellular matrix and prostaglandins [77]. The post-
coitum inflammatory response mediates the emigration and efflux of neutrophils 
into the uterine lumen to ensure the clearance of microorganisms and seminal 
debris, promoting sperm survival by phagocytosing dead, abnormal and non-
fertilizing sperm [78].  
The chemokines present in semen, and those locally induced by semen in the 
FGM, trigger the recruitment of leukocytes into the FGM. Increased expression of 
the genes encoding the chemokines granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and CXCL8, and the pro-inflammatoty cytokines IL-1α and IL-6 
has been reported in cervical tissue after unprotected coitus [75]. These and other 
genes, such as CCL2, macrophage inflammatory protein (MIP)-3α (CCL20) and IL-
10, were previously demonstrated to be up-regulated by seminal plasma in cervico-
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vaginal epithelial cell lines  [79, 80] and tissue explants [81]. In the latter study up-
regulation of CXCL8 and IL-10 in cervico-vaginal tissue by semen has been 
attributed to its abundant content in prostaglandin-E (PGE). Among the cytokines 
induced by semen deposition onto the FGM, GM-CSF targets the pre-implantation 
embryo to promote blastocyst formation, increasing the number of viable 
blastomeres by inhibiting apoptosis and facilitating glucose uptake [61].  
To date, the active signaling components of human semen responsible for 
stimulating the FGM immune response are unidentified. Protein chromatographic 
techniques and neutralizing antibodies have identified TGF-β as the principal 
mediator of the induction of uterine inflammatory responses following mating in 
mice [82]. Recently a comprehensive gene expression study performed by Sharkey 
et al. [83], revealed that TGF-β accounts for the up-regulation of GM-CSF and IL-6 
caused by exposure of cervico-vaginal epithelial cells to semen in vitro, while 
regulation of the production of cytokines such as CXCL8, CCL2, CCL20 and IL-1α 
depends on other seminal factors. TGF-β has also been identified as an important 
player in establishment of tolerance to paternal antigen by regulating the 
proliferation of T regulatory cells, which role is considered important for fertilization 
of the egg and early pregnancy [76].  
1.3.5 Sources of seminal HIV-1 
HIV-1 can be present in semen as cell-associated virus, carried by infected 
leukocytes or bound to spermatozoa plasma membrane, and cell-free virus. 
Genomic sequence analysis of cell-free HIV-1 variants found in semen of 
chronically infected individuals revealed that these viruses originate from multiple 
sources: direct import from the blood stream, oligoclonal amplification within the 
male genital tract, and compartmentalization [84, 85]. It was also shown that some 
of the cell-free HIV-1 variants were different from those isolated from infected 
leukocytes present in semen [86]. All these data support the idea that in the male 
genital tract there are sources of HIV-1 production other than the HIV-1 infected 
cells found in semen and infection of the genital organs actively contributes to viral 
shedding in semen. However, the infectiousness and the role of cell-free and cell-
associated virus in HIV-1 transmission have been poorly investigated and remain 
matter of debate. 
1.3.5.1 Cell-associated HIV-1 
1.3.5.1.1 Leukocytes 
Leukocytes enter semen from various sites along the reproductive tract, including 
the rete testis, epididymis, prostate, and urethra, where they play an 
immunosurveillance role. Concentrations of leukocytes in semen are highly 
variable. Leukocytospermia, an asymptomatic genital inflammatory condition 
characterized by more than 106 leukocytes/mL semen occurs in approximately 5-
10% of healthy non-HIV-infected men and as many as 24% of HIV-infected men 
[87, 88]. Some studies indicate that semen from healthy non-HIV-infected men 
contains on the order of 105 leukocytes/mL, the majority of which are 
polymorphonuclear leukocytes [55] although substantial numbers of macrophages 
and CD4+ T cells are also present. Macrophages usually outnumber CD4+ T cells 
in semen, and this is especially the case in HIV-infected men in whom seminal 
CD4+ lymphocytes are depleted (Tab 1.3.2) [89]. These data indicate that 
macrophages are the most abundant HIV-susceptible host cell in semen and a 
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likely principal mediator of cell-associated HIV transmission. HIV-infected cells 
have also been detected in pre-ejaculatory fluid, a urethral secretion secreted from 
the glands of Littre and Cowper glands during sexual stimulation, and these may 
also facilitate the sexual transmission of HIV [90].  
 
 HIV-negative (n=17) HIV-positive (n=98) 
Total leukocytes 170000 [9000-20520000] 
104000  
[0-55380000] 
Monocytes/ 
macrophages 
52000  
[300-998000] 
22000  
[0-24349000] 
CD4+ T cells 4000 [0-52000] 0 [0-6187000] 
CD8+ T cells 2000 [0-57000] 0 [1547000] 
 
Table 1.3.2 Leukocytes concentration in semen. (From Anderson et al., 2010 [88]). 
 
To date, the percentage of HIV-infected leukocytes in semen has not been 
determined. Only a few studies have used HIV DNA PCR assays to assess the 
prevalence or number of HIV-infected cells in semen. In these studies, the 
prevalence of HIV-1 proviral DNA in semen samples has ranged from 21 to 65% 
and the amount of HIV DNA has ranged from not detectable to 80000 copies/mL 
[88]. After initiation of HAART, levels of both HIV-1 RNA and DNA are reduced in 
semen, although HIV proviral DNA-bearing cells can persist in semen for several 
months and have been shown to be infectious in vitro [91].  
1.3.5.1.2 Spermatozoa 
The nature of HIV-1 interaction with spermatozoa is still matter of debate. Most 
studies failed to detect HIV-1 nucleic acids within purified motile spermatozoa, 
indicating that the few positive results reported represents either false positives or 
very rare events [88, 92]. It is generally accepted that HIV-1 does not productively 
infect motile spermatozoa. However, a recent study demonstrated the presence of 
HIV DNA in ejaculated spermatozoa with abnormal morphology [93]. This 
phenomenon may be explained by the fact that mammalian spermatozoa 
spontaneously take up foreign DNA or RNA in the absence of seminal plasma (e.g. 
epididymal spermatozoa). One hypothesis is that non-specific uptake of HIV 
RNA/DNA by epididymal spermatozoa would lead to abnormal spermatozoa prone 
to cell death. These defective sperm could potentially introduce HIV-1 to 
phagocytic macrophages or other cells in the female genital tract after intercourse. 
Alternatively, this detection may result from specific interactions between HIV and 
spermatozoa (see section 1.3.6.2.2).  
1.3.5.2 HIV-1 detection within the organs of the MGT 
Anatomical sites and sources of seminal HIV-1 are largely unknown. Most of our 
knowledge on this topic comes form indirect evidences, such as detection of viral 
RNA in secretions of genital organs and swabs, non-human primates models, and 
human explants infected ex vivo.  
Recent data showed that the testis is infected early during the course of HIV-1 
infection. Roulet et al. developed a system for infecting and maintaining in culture 
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human testis ex vivo, in which productive replication of the virus was observed [94]. 
The main virus-producing cells in this culture model are the resident testicular 
macrophages. An in vivo study of SIV-infected macaques confirmed the productive 
infection of the testis during the asymptomatic chronic stage and revealed that this 
infection occurs during the acute primary infection [95]. Because seminal shedding 
of HIV RNA and HIV DNA continues after vasectomy [96], distal genitourinary 
anatomic sites are likely important sources of seminal HIV.	  Early studies showed 
evidence of HIV and SIV in immune cells infiltrating the epididymis, prostate and 
seminal vesicles of men or macaques at the AIDS stage [92]. All these organs are 
infected very early and produce viral particles. The infection persists during the 
chronic stage and its intensity is positively correlated with the blood viral load. 
Infected cells are mainly T lymphocytes and to a lesser extent, macrophages. The 
infected immune cells are mainly localized within the stroma of the organs but are 
also found inserted within the epithelium, a finding most common within the 
epididymis. Their localization within the secretory epithelium could lead to the 
release of free viral particles and infected cells in the lumen, and therefore in the 
seminal plasma during ejaculation. As prostate and seminal vesicles secretions 
account for respectively 30% and 60% of the seminal fluid (see section 1.3.1), 
these two organs have been thought to represent the main source of virus in 
semen. It was confirmed that human prostate [97] and seminal vesicles [98] are 
susceptible to HIV-1 infection ex vivo and in vivo, although on the basis of a 
comprehensive study of prostatic secretions of men without urethritis who shed 
HIV in their seminal plasma, distal genitourinary sources other than the prostate 
appear to be the major source of seminal HIV-1 [99].	  
1.3.5.3 Infectiousness of seminal HIV-1 
A number of laboratories have cultured HIV from both seminal cells and cell-free 
seminal plasma. Overall, the recovery rate of infectious HIV from seminal cells has 
been much higher (median 20%, range 4–55%) than that from seminal plasma 
(median 5.9%, range 3–11%) [88]. The relatively low HIV recovery rate from 
seminal plasma contrasts with quantitative PCR data indicating that HIV 
prevalence rates and viral copy numbers are higher in seminal plasma than in the 
semen cell fraction [88]. Although it has been proposed that this discrepancy would 
indicate that cell-free HIV in semen is replication incompetent or inactivated, the 
low culture rate could also reflect the toxicity of seminal plasma to peripheral blood 
mononuclear cell (PBMC) target cells used for culturing HIV [100]. Moreover, HIV-1 
RNA levels in semen have been correlated to the risk of transmission (see section 
1.5.2.2). Whether this reflects also changes in cell-associated HIV-1 is not known. 
To date no study was able to define the weight and the role of cell-free and cell-
associated virus in HIV-1 sexual transmission and current models still need to be 
improved to address this important topic.  
1.3.5.4 HIV-1 reservoir in the MGT 
HIV-1 heterosexual transmission decreases remarkably following HAART. 
However, the existence of viral sanctuaries prevents the full eradication of the virus 
from the body. A viral sanctuary is either an anatomical or a cellular site (e.g. 
latently infected resting memory lymphocytes), impermeable to the action of one or 
several antiviral drugs and within which the virus replicates or persists despite 
treatment. Such sanctuaries are called reservoirs when they replenish the body in 
free virus or infected cells.  
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In semen, some viral inhibitors display sub-optimal concentrations, sometimes 
leading to the emergence of drug-resistant strains and to their sexual transmission 
[92]. The testis is a well-known pharmacological sanctuary in which HIV inhibitors 
have restricted access and several studies indicate that the MGT may constitute a 
viral reservoir responsible for HIV shedding in semen. Although in most patients 
HAART can reduce the semen viral load to an undetectable level [101], the 
persistence of HIV RNA and/or infected cells in semen has been reported in up to 
10% of men under various antiretroviral treatment combinations, despite an 
undetectable blood viral load [91, 102]. The residual viral load detected in semen is 
generally low but appears to be extremely variable amongst individuals (range of 
0.6 log to 5 log of HIV RNA copies/mL), because depends on many factors that 
globally affect the efficiency of sexual transmission (see section 1.5.2.2).  
This persistence of HIV excretion in the semen of a subset of individuals under 
HAART has potentially important consequences for the transmission of the virus. 
Indeed, the possibility of transmitting HIV-1 despite an undetectable blood viral 
load following HAART remains in a subset of patients, as illustrated by the case 
report of an homosexual man under effective HAART who contaminated his 
partner [103]. 
1.3.6 Role of semen in HIV-1 transmission to the FGM 
In vitro an in vivo studies identified a number of factors in human semen that can 
inhibit or enhance HIV-1 transmission. Most of these studies investigated the effect 
of whole semen or seminal plasma from HIV-uninfected individuals on the 
replication lab-adapted HIV-1 variants, thus ignoring some important changes in 
semen characteristic induced by HIV-1 infection of the MGT. Moreover, the choice 
of the system to investigate these effects is critical due to the nature of the 
reproductive act and of the female genital mucosa, and the global effect of semen 
on HIV-1 transmission may be different depending on many other factors that 
affect donor infectiousness and recipient susceptibility (see section 1.5.2). 
1.3.6.1 Inhibitory effect  
1.3.6.1.1 Cationic polypeptides  
Cationic antimicrobial polypeptides produced by mucosal surfaces, such as 
secretory leukoprotease inhibitor (SLPI), defensins and lactoferrin, have been 
found to have anti-HIV-1 properties [104]. Martellini et al. demonstrated that SP 
contained 52 individual cationic polypeptides, which contributed to its aggregate 
anti-HIV-1 activity, and that SP maintained anti-HIV-1 activity, even when diluted 
3200-fold [105]. However, this phenomenon was transient, as whole SP incubated 
for over 24 hr exhibited a reduction in anti-HIV-1 activity. 
1.3.6.1.2 Seminal plasma interferes with the attachment of HIV-1 to DC-SIGN 
DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) is 
expressed by stromal DCs in the FGM and appears to be a universal pathogen 
receptor, which was described to mediate the uptake of HIV-1 virions, protecting 
them from degradation, and efficiently promote infection of CD4+ T cells (see 
section 1.5.1.2). Sabatte et al. found that human seminal plasma, even when used 
at very high dilutions (1:104 to 1:105), abrogates the recognition of HIV-1 by DC-
SIGN [106]. Not only the binding of HIV-1 to monocyte-derived DCs (which express 
high levels of DC-SIGN) but also the transmission of HIV-1 from DCs to T CD4+ 
cells was markedly inhibited by seminal plasma. The inhibitory effect appeared to 
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be specific for DC-SIGN since no inhibition was observed using DC-SIGN-negative 
target cells. Semen clusterin accounts, at least in part, for the inhibitory effect of 
semen on the capture of HIV-1 mediated by DC-SIGN [107]. 
1.3.6.2 Enhancing effect  
1.3.6.2.1 Neutralization of acidic vaginal pH 
The healthy vagina is colonized with lactobacilli producing lactic acid, which 
creates an acidic pH environment (pH 4.0-6.0) necessary to maintain the resident 
microbiome and combat pathogens. Cell-free and cell-associated HIV-1 and are 
rapidly inactivated in vitro at acidic pH levels [108]. O’Connor et al. demonstrated 
that laboratory strains of HIV-1 were uniformly stable at pH of 5.0–8.0, with mild 
reduction in infectivity (25%) at pH 4.5 [109]. After ejaculation, semen increases 
the pH of the vaginal fluid to neutral or higher levels within 30 seconds, maintaining 
an increased pH level for up to 2 hours [44, 110], and thus promoting HIV-1 
survival and infection. 
However, studies done with primary isolates instead of laboratory strains showed a 
high variability of HIV-1 to inactivation by acidic pH. In fact, for certain isolates, it 
was reported that the infectivity of HIV-1 was enhanced after exposure to pH 4.0–
5.0 [111]. 
1.3.6.2.2 Spermatozoa bind and transmit HIV-1 
Although CD4 is absent on spermatozoa membrane, alternative molecules have 
been described to bind HIV-1: GalAAG, a glycolipid related to galactosylceramide, 
CCR5, mannose receptors, and eparan sulfate [92]. Ceballos et al. reported that 
spermatozoa greatly enhance the infection of DCs by HIV-1 [112]. Spermatozoa 
efficiently attach and transmit the virus to DCs through heparan sulfate molecules 
expressed on the surface of spermatoza. Interestingly, spermatozoa-attached 
virions are also efficiently transmitted to macrophages and CD4+ T cells. Of note, 
acidic pH similar to those found in the vagina after sexual intercourse markedly 
increase the binding of HIV-1 to the spermatozoa surface and the consequent 
transmission of HIV-1 to CD4+ target cells. 
1.3.6.2.3 Electrostatic interactions  
Screening a complex peptide/protein library derived from human seminal fluid to 
determine possible inhibitors and enhancers of HIV-1 infection, Munch et al. found 
that naturally occurring fragments of the semen protein prostatic acidic 
phosphatase (PAP) form amyloid fibrils, termed semen-derived enhancer of virus 
infection (SEVI), which markedly increased HIV-1 infection [113]. SEVI has eight 
basic residues, which make it highly cationic (isoelectric point = 10.21), an 
important property for its attachment effects [114, 115]. The positively charged 
SEVI fibrils bind to both target cells and HIV-1 virions and augment infection by 
increasing physical contact between these entities, similar to the manner in which 
synthetic cationic polymers promote retrovirus attachment to target cells [115].  
SEVI appears to act as a general enhancer of HIV-1 infection. It increases the 
infection by R5-, X4- and dual tropic HIV-1 clones in peripheral blood mononuclear 
cells (PBMCs), macrophages, DCs and human lymphoid tissue explants. 
Moreover, SEVI enhances HIV infection in a dose- and time-dependent manner, 
and its effects are seen across different envelopes [116]. Importantly, the 
enhancing effect of SEVI was most pronounced at low concentrations of virus, 
resembling conditions of sexual HIV-1 transmission. Infection enhancement, 
however, appears to be donor dependent. The effect of SEVI enhancement was 
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tested in hCD4/hCCR5-transgenic rats inoculated with either HIV-1 YU2 or SEVI-
treated HIV-1 [113]. Tail vein inoculation with SEVI-treated HIV-1 increased the 
cDNA copy numbers in splenectomy extracts by five fold. 
1.3.6.2.4 Proinflammatory effects  
The immediate reaction of semen deposition into the mammalian reproductive tract 
is a dramatic influx of inflammatory cells, and a strong induction pro-inflammatory 
cytokines and chemokines (see section 1.3.4). Interestingly, it is becoming 
increasingly clear that different normal reproductive processes such as ovulation, 
menstruation, implantation and parturition display hallmark signs of inflammation 
[117, 118]. Whether or not the inflammatory responses induced by semen 
deposition in the mucosa affect the course of the early events involved in the 
fertilization or the implantation processes remains to be determined. Similarly, 
these inflammatory responses may contribute to the transmission of HIV-1 and 
other sexually transmitted infectious diseases through disruption of the epithelial 
barrier, and by inducing the local recruitment of CD4+ target cells.  
Berlier et al. have demonstrated that seminal plasma also induces the expression 
of CCL20, a key chemotactic factor involved in recruitment and maturation of 
Langerhans cells and dendritic cells [79], which some investigators consider to be 
the first target cells for HIV genital mucosal infection [119] or somehow involved in 
promoting HIV-1 transmission in its early stage [120]. 
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1.4 The female genital tract 
The female genital or reproductive tract (FGT) has evolved into separate 
compartments consisting of ovaries, fallopian tubes, uterus, cervix and vagina (Fig. 
1.4.1), which function is precisely regulated by the endocrine system. Each of 
these sites is designed to carry out different functions related to conception: 
production and transportation of the oocytes, fertilization, implantation, pregnancy 
and menstruation. In addition to its reproductive task, the FGT represents a barrier 
against pathogens and the female genital mucosa (FGM) displays unique features 
among mucosal sites, which allow the immune system to fight and control 
infections without interfering with the events that surround conception. 
 
 
 
Figure 1.4.1 Anatomy of the female genital tract. (From http://health.allrefer.com). 
1.4.1 Anatomy of the sites of HIV-1 infection in the FGT 
Ex vivo studies using human tissues and pathogenic models of HIV-1 transmission 
in non-human primates (NHPs) showed that HIV-1 can infect the mucosa of the 
vagina and of the uterine cervix, either ectocervical and endocervical mucosa, 
although the relative contribution of these three sites to successful transmission 
remains unknown and debated. HIV-1 and its homologs in NHPs, the simian 
immunodeficiency viruses (SIVs), can establish infection solely penetrating the 
vaginal epithelium, as show in a woman born without a uterus [121] and in Rhesus 
Macaques challenged intra-vaginally after surgical hysterectomy [122]. However, 
studies in Rhesus Macaques demonstrated predominant early SIV RNA+ cell foci 
within the endocervix [120, 123]. Rather than a controversy, these data may reflect 
the ability and flexibility of HIV-1/SIV to circumvent different defensive barriers of 
the FGT. 
1.4.1.1 The vagina 
The vagina is a fibromuscular tube that extends from the uterus to the external 
genitals (vulva) and whose anterior (front) and posterior (rear) walls are normally in 
contact with one another [56]. The vaginal wall consist of three layers: the mucous 
membrane, composed of stratified squamous nonkeratinized epithelium and an 
underlying lamina propria of connective tissue; the muscular layer, composed of 
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smooth muscle fibers disposed both longitudinally and circularly; the adventitia, a 
dense connective tissue that blends with the surrounding fascia. Although there is 
wide anatomical variation, the length of the unaroused vagina of a woman of child-
bearing age is approximately 6 to 7.5 cm across the anterior wall, and 9 cm long 
across the posterior wall. During sexual arousal the vagina expands in both length 
and width. Its elasticity allows it to stretch during sexual intercourse and during 
birth to offspring. 
The stratified squamous epithelium of the vagina is several layers thick. The basal 
layer is a single layer of cylindrical cells with oval nuclei. Above this area are 
several layers of polyhedral cells and above these are more layers of cells that are 
more flattened in appearance and accumulate glycogen in their cytoplasm. They 
also exhibit keratohyalin granules intracellularly, although this tendency to 
keratinization is not normally completed in the vaginal epithelium and the surface 
cells always retain their nuclei. The most superficial cells are desquamated into the 
vaginal lumen where their intracellular glycogen is converted into lactic acid, 
probably by the bacteria that normally colonize the vagina. The resulting acidity is 
important in protecting the FGT from infections.  
Before puberty and after menopause, when estrogens levels are low, the 
epithelium is thin and the pH is higher than in the reproductive years. Indeed 
estrogens stimulate the production of glycogen, which results in low pH, and 
maintain the thickness of the entire epithelium, thus representing and important 
determinant of the FGM susceptibility to infection (see section 1.5.2).  
1.4.1.2 The uterine cervix 
The uterus has two major components: the expanded upper two-thirds of the 
organ, the body of the uterus, and the cylindrical lower one-third, the cervix [56]. 
These two parts are rather different from one another in their structure and 
function. The fundus is the rounded upper part of the body and the isthmus is the 
short, slightly constricted zone between the body and the cervix. Here we will focus 
our attention mainly on the cervix.  
The cervix consists primarily of dense collagenous connective tissue. Only about 
15% of its substance is smooth muscle. In the isthmus, the uterine lumen narrows 
down to form the internal os. Below this point the lumen widens slightly to form the 
cervical canal or endocervical canal that measures 7 to 8 mm at its widest. Finally, 
a constricted opening, the external os, at the lower end of the cervix provides 
communication between the lumen of the cervix and that of the vagina (Fig. 1.4.1). 
This protruding portion of the cervix projects into the vagina through the upper 
anterior vaginal wall and is referred to as portio vaginalis or ectocervix. On 
average, the ectocervix is 3 cm long and 2.5 cm wide.  
The epithelium of the cervix is varied. The ectocervix is covered by stratified 
squamous nonkeratinized epithelium. Usually, in older women, this type of 
epithelium extends from a very short distance into the cervical canal, where it 
forms a rather abrupt junction with the simple columnar epithelium lining the rest of 
the endocervical canal (Fig. 1.4.2). The site of the squamocolumnar junction, called 
tranformation zone, varies as well. It may occur higher up in the cervical canal, or 
the columnar epithelium may actually extend out beyond the external os where it 
forms small patches known as physiologic eversion, or ectopy, on the vaginal 
surface of the cervix. Ectopy is usually present in adolescents, when the 
endocervix moves out of the uterus, and decreases in post-menopause women, 
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when the uterus shrinks moving the transformation zone upwards. Changes 
(metaplasia) of the transformation zone may occur also with the changes of the 
cervix associated with the menstrual cycle.  
 
 
Figure 1.4.2 Transformation zone of the uterine cervix. This particular portion of the 
female genital mucosa is thought to be a preferential site for HIV-1 infection due to 
its physical and immunological properties. (From Hladik & McElrath, 2008 [42]).  
 
Inside the cervix, the endocervical mucosa is arranged in a series of folds and 
ridges. The mucosa also contains large branched endocervical glands, that are not 
true glands but are merely grooves, called crypts, that serve to increase the 
surface area of the mucosa. During childbirth, contractions of the uterus will dilate 
the cervical canal up to 10 cm in diameter to allow the child to pass through. The 
epithelium of the both the mucosal surface and the crypts is of the simple columnar 
type in which almost all the cells are mucus secreting. A few ciliated cells are 
present. If the ducts of the glands become blocked, mucous secretion accumulate 
inside them to form small lumps just under the surface.  
Unlike the mucosa of the body of the uterus the endocervical mucosa does not 
slough off at menstruation. It does, however, respond to cyclic changes in the 
levels of the ovarian hormones. It secretes up to 60 mg of mucus a day throughout 
much of the cycle, but near the time of ovulation (midcycle), when estrogen 
secretion reaches a peak, the secretion rate increases 10-fold and the aboundant 
clear mucus fills the cervical canal. It is less viscous then at other times during the 
cycle and it is easily penetrated by spermatozoa. The production of progesterone 
by the corpus luteum after ovulation (or during pregnancy) changes the quantity 
and properties of mucus produced. It becomes more viscous, less abundant and 
much less penetrable by spermatozoa, acting as a plug to seal off the uterine 
cavity.  
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1.4.2 Immune defenses of the FGM 
The mucosa of the FGT is a component of the mucosal immune system, an 
integrated network of specialized cells and tissues that employs specialized 
immune defense mechanisms at mucosal surface (Table 1.4.1). There are 3 lines 
of defense that the FGM evolved to fight and control infections: the epithelial 
barrier, innate immunity, and adaptive immunity mechanisms. 
 
 
Cellular immunity 
Epithelium Genital secretions 
T M LC 
Endocervix +++ +++ ++ Simple columnar 
Mucins, cytokines,  
lysozime, lactoferrin, 
defensins, SLPI, 
IgG, IgA, 
pH<0.5 
Ectocervix ++ ++ ++ Stratified  
squamous  Vagina + ++ ++ 
 
Table 1.4.1 Some of the mediators of immunity in the female genital mucosa.  
T = T cells; M = macrophages; LC = Langerhans cells; Ig = immunoglobulin; 
SLPI = serine leukocyte protease inhibitor. 
 
1.4.2.1 The epithelial barrier 
1.4.2.1.1 Epithelium 
The epithelial lining of the FGM, made up of epithelial cells and mucus, provides a 
robust physical and immunological barrier against pathogens. As discussed above, 
epithelial structures vary depending on their localization. The nonketarinized 
stratified squamous epithelia of the vagina and the ectocervix are multilayered 
structures of (up to 300 µm thick) consisting of a layer of basal germinative cells 
resting on a basal lamina (a 20-100 nm layer of extracellular material), which 
separates the epithelium from the underlying vascular connective tissue called the 
lamina propria. A lack of tight junctions in the squamous epithelial layers permits 
the movement of small molecules within epithelial spaces within the cells [124]. 
The continuous sloughing of the superficial layers of the stratified epithelium 
prevents many pathogens from colonizing and establishing infections. 
The epithelium lining the endocervical canal is simple columnar, a single layer of 
polarized epithelial cells with apical tight junctions. A number of factors have been 
described to affect the integrity of this barrier. For example estradiol, the 
proinflammatory cytokine tumor necrosis factor (TNF)-α, and other factors secreted 
by the underlying stromal cells, which are also under hormonal control, 
compromise transepithelial resistance, leading to increased pathogen translocation 
across the epithelium [125, 126]. Physical and chemical trauma and ulcerating 
infections can cause epithelial disruption that provides pathogens access to 
unprotected cells in the germinal layer and lamina propria (see section 1.5.2.1). 
Epithelial disruptions and cervical ectopy are indeed major risk factors for HIV-1 
transmission. 
1.4.2.1.2 Mucus 
Epithelial cells of the FGM secrete several biological factors that create an 
inhospitable environment for pathogens, including a layer of mucus that lubricates 
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and reinforces the epithelial barrier. Mucus obtains its structural characteristics 
from mucins, a family of hydrophilic glycoproteins that contain tandem repeats of 
serine- and threonine-rich domains, which are sites of attachment of O-glycan 
attachment. Encoded by MUC gene family, to date 18 mucin genes have been 
cloned and two classes of mucins have been identified: membrane-associated 
mucins and secreted mucins, which include large gel-forming and small soluble 
mucins [56]. Membrane-associated mucins are expressed at the apical surface of 
epithelial cells throughout the FGM and form a dense glycocalyx. Negatively 
charged carbohydrate residues on the mucin protein backbone confer disadhesive 
properties. Among secreted mucins, the gel-forming mucins are formed by multiple 
mucins monomers linked one another with lengths up to several microns and 
molecular weights ranging from 0.5 to 200 Mda.  
The composition of the mucus in the FGT is affected by a number of factors 
comprising tissue-specific posttranslational processing, genetic polymorphisms, 
endocrine status, infection and inflammation. For example, the expression of the 
large gel-forming mucin MUC 5B by the endocervix and its glycosylation are 
upregulated by estrogen, accounting for the large volume of watery mucus in the 
endocervical canal at the time of ovulation that permits sperm movement [127]. 
Mucins can adhere directly to microorganism, such as Candida albicans, through 
their glycosylated domains and impede their attempts to colonize the epithelium []. 
Mucins fibers are densely packed in the glycocalix and exclude 30 nm-sized 
particles, representing an effective barrier against virus penetration. Mucins fibers 
are less dense in gel-forming secreted mucins and the space between midcycle 
cervical mucus fibers (20-200nm) is large enough for proteins and small viruses 
(HIV is 100 nm in diameter) to diffuse [128, 129]. Another important factor that 
affects microorganism penetration through cervicovaginal mucus is pH. The acidic 
environment of the vagina has been shown to slow the rate of HIV diffusion by 
abolishing the negative surface charge of the virus. I presence of semen, which 
has a pH closer between 7 and 8, HIV retains its negative surface charge resulting 
in higher rate of diffusion [130]. 
Intersperse within mucins fibers is an acqueus phase containing antimicrobials and 
immunoglobulins. Antibodies, especially polyvalent IgA and IgM, can agglutinate 
pathogens into clusters that are too large to diffuse through mucus. Secreted 
antibodies bind to mucins through low-affinity molecular bonds with the Fc and SC 
components of the molecules and through interactions with mucin-like-IgG Fc 
binding protein that is found in most mucosal secretions [131]. 
1.4.2.2 Innate immunity 
The innate defenses of FGM consist of cells that constitutively express 
antimicrobial factors and/or rapidly mount antimicrobial responses triggered by 
recognition of highly conserved molecular motives present on microorganisms. The 
principal effector cells of innate immunity at the mucosal surface are dendritic cells 
(DCs), macrophages, neutrophils and natural killer (NK) cells. 
1.4.2.2.1 Pathogen-recognition receptors 
The cells of innate immunity are able to discriminate pathogen-associated 
molecular patterns (PAMPs), such as nucleic acids (i.e. double-stranded RNA, 
unmethylated CpG DNA sequences), aminoacidic patterns (N-formylmethionine), 
carbohydrates (tecoic acid), and lipids (lipopolysaccharide) that are found in 
microbes but not in mammalian cells, through cellular receptors known as 
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pathogen-recognition receptors (PRRs) [132]. These receptors are encoded in the 
germ line and have a more limited repertoire than receptors of adaptive immunity.   
The proteins of the complement system represent a front line of defense in against 
extracellular pathogens by opsonizing microbes for clearance by phagocytes 
through their complement receptors. Another class of PRRs, the C-type lectins, 
allows phagocytes to ingest microbes via recognition of pathogens-associated 
carbohydrates. Members of this class of proteins found on DCs, such as langerin 
and Dendritic Cell-Specific Intercellular adhesion molecule 3-Grabbing Non-integrin 
(DC-SIGN), have been described to play a role in HIV-1 transmission (see sections 
1.3.6.1.2 and 1.5.1.2.1). Intracellular PRRs include the Nucleotide-binding 
Oligomerization Domain (NOD)-like receptor gene family, active against 
intracellular bacteria, and a family of RNA helicases called Retinoic acid Inducible 
Gene I (RIG-I)-like receptors that detect viral infections leading to production of 
type I Interferons.  
The most prominent and best characterized PRRs are the Toll-like receptors 
(TLRs), a family of trans-membrane proteins that are expressed by almost all the 
immune cells, and by some non-immune cells. To date more than 10 TLRs have 
been identified in humans and their localization in the cell is associated with the 
type of PAMP recognized: TLRs 1, 2, 4, 5 and 6 are expressed on the cell plasma 
membrane and recognize products of bacteria, fungi, protozoa and mycobacteria; 
TLRs 3, 7, 8 and 9 reside in endosomal and lysosomal membranes and recognize 
nucleic acids of viruses and bacteria [133]. The binding of TLRs leads to the 
activation of an acute inflammatory response mediated by the induction of genes 
coding for antimicrobial proteins, proinflammatory cytokines, type I interferons and 
chemokines, through a signal transduction pathway highly conserved. The 
consequential recruitment of effector cells, such as neutrophils and macrophages, 
favors the elimination of microorganisms and the induction of co-stimulatory 
molecules on antigen presenting cells, bridging innate and adaptive immunity  
[134]. Various TLRs have been characterized in female genital mucosa cells: TRLs 
are expressed by macrophages, DC, NK, B and T cells and can also be expressed 
by epithelial cells [135]. Despite the important anti-viral function of TLRs and other 
innate receptors, their role in HIV infection of the female genital tract has not been 
deeply investigated. Expression of TLRs 3, 7, 8 and 9, among other PRRs, has 
been detected in epithelial cells of the ectocervix and endocervix [136], thus they 
may play an important role in triggering the early immune response against 
viruses. It has been reported that plasmacytoid dendritic cells (pDCs) are among 
the first cells to sense HIV-1 through TLR9, inducing the production of type I 
interferons [137]. Although HIV-1 also activates the TLR 7 and 8 pathways [138], 
other PRRs specific for PAMPs from pathogens infecting the cervico-vaginal 
mucosa or present in semen may have an important role in affecting the local 
immune response during HIV-1 transmission [139]. 
1.4.2.2.2 Leukocytes 
DCs and macrophages are professional antigen-presenting cells (APCs) and are 
important for the generation and regulation of the adaptive immune functions. 
Pathogen exposure and phagocytosis induces APCs maturation, through activation 
of their PRRs, and antigen presentation on type Human Leukocytes Antigens 
(HLAs) complexes to naïve T cells, which results in expansion of pathogen-specific 
adaptive immunity. Among DCs, Langerhans cells (LCs) are immature dendritic 
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cells localized within the layers of the stratified squamous epithelium of vagina and 
ectocervix [140]. They have high endocytic activity and low T cell activation 
potential and are characterized by the presence of Birbeck granules, which are 
cytoplasmic organelles which function is still unknown. LCs have dendrites that 
extend and retract through the intercellular spaces ad that can even reach up to 
the surface of the epithelium [141]. LCs express CD4, CCR5 and langerin, that 
have been described to mediate HIV-1 entry into these cells, although productive 
infection, if it occurs, appears inefficient (see section 1.5.1.2.1). Myeloid dendritic 
cells (mDCs) and plasmacytoid dendritic cells (pDCs) are two other types of DCs 
that reside in the sub-epithelial stroma of the FGM [56]. mDCs, once activated by 
recognition of pathogens that penetrated through the mucosa, migrate to regional 
lymph nodes where they function as APCs and activat naïve T cells. pDCs, as 
reported above, have an important role in early detection and response against 
viral infection and are major producers of type I interferons. Stromal DCs exhibit 
different HIV-1 receptor expression patterns compared to LCs because they 
express DC-SIGN in addition to CCR5, thus potentially permitting alternative entry 
pathways for HIV (see section 1.5.1.2.1). 
Macrophages localize in the lamina propria of the FGM and account for 10% of the 
leukocytes present in the FGT [135]. Long-lived tissue macrophages are derived 
form blood monocytes and recruited to the to the sub-epithelial stroma by 
endogenous chemoattractants in the non-inflamed mucosa. These resident 
macrophages have down-regulated expression of PRRs and low expression of pro-
inflammatory cytokines, but retain their phagocytic and anti-microbial functions. A 
different population of macrophages is recruited to the site of infection in the FGM 
by inflammatory chemokines. These cells express abundant PRRs and secrete 
pro-inflammatory cytokines, amplifying the immune response [56].  
The most represented granulocytes in the FGM are neutrophils. They are present 
throughout the FGT and their number progressively decreases from the upper to 
the lower genital tract [135]. Neutrophils express a wide array of TLRs and at the 
site of infection they respond to pathogens through phagocytosis, release of 
preformed cytoplasmic granules that contain antimicrobial peptides and of reactive 
species of oxygen and nitrogen, and secretion of cytokines and chemokines that 
recruit and activate additional immune cells [56]. 
NK cells constitute a major component of the innate immune system and play an 
important role in the recognition and killing of cancer cells and virally infected cells. 
Within the FGT, NK cells demonstrate different phenotypic characteristics. The 
number of NK cells varies in the endometrium across the menstrual cycle, reaching 
a peak of approximately 70% of the total leukocyte population in the secretory 
phase [135]. NK cells express most of the TLRs and NOD proteins, and kill target 
cells through the release of lytic proteins such as perforin and granzymes. Type I 
interferons play a critical role in NK cells activation, as well as IL-2, IFN-γ and IL-12 
[56].  
1.4.2.2.3 Anti-microbial peptides 
Secretions of the FGT contain several peptides with broad anti-microbial activity 
that prevent and/or reduce infection by killing or controlling the growth of 
microorganisms by direct or indirect mechanisms [124]. They include defensins, 
enzymes (e.g. lysozime), anti-proteases and chemokines (e.g. β-chemokines). 
Defensins are small cationic antimicrobial peptides active against bacteria, fungi 
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and enveloped viruses. They are classified in two groups α- and β-defensins, 
depending on their structure, and are secreted by immune cells, such as 
neutrophils, and epithelial cells of the FGM [135]. Defensins exert their anti-viral 
activity by directly binding to the viral membrane of enveloped viruses or indirectly 
through the recruitment and activation of immune cells [142]. Serine Leukocyte 
Protease Inhibitor (SLPI) is a member of the trappin gene family and is produced 
primarily from epithelial cells, neutrophils and activated macrophages. It has a 
broad anti-microbial activity and it has been described to protect macrophages and 
CD4+ T cells from HIV-1 infection [124].  
1.4.2.3 Adaptive immunity 
The cellular components of the acquired immune system of the FGT are two: T 
cells, and antibody secreting plasma cells. Adaptive immunity is induced 
specifically against one pathogen following presentation and stimulation of T cells 
by APCs. A number of cells in the FGT have been shown to present antigens on 
HLAs molecules. These include classical APCs including macrophages, dendritic 
cells and Langerhans cells, but also epithelial cells of the cervix and endometrium. 
Adaptive immunity includes Th1 (cell-mediated), Th2 (humoral), T regulatory and 
Th17 responses. 
In the FGM, CD8+ T cells (35-50%) predominate over CD4+ T cells (25%) and are 
numerous within the epithelium of the ectocervix, vagina and transformation zone 
[122, 124]. Substantial infiltrates of CD8+ and CD4+ T cells are seen in the stroma 
of the transformation zone, but T cells are relatively sparse in the stroma of the 
ectocervix and vagina. The transformation zone of the cervix has been indentified 
as a major inductive and effector site of cellular immunity in the lower FGT due to 
the particularly high number of T lymphocytes and APCs resident therein [140]. 
Phenotypic analysis of the lymphocytic subsets isolated from human cervico-
vaginal explants, revealed that FGM-resident CD4+ T cells are predominantly 
effector memory and terminal effector memory, with almost complete absence of 
naïve and central memory cells [143]. These cells expressed high levels of CCR5 
as well as CXCR4. The same study identified a higher proportion of terminal 
differentiated memory cells among CD8+, compared to CD4+ T cells, that express 
higher levels of the activation markers CD38, HLA-DR, and CD57.  
CD4+ helper T cells play a role in humoral immunity by driving B cell maturation to 
antibody secreting plasma cells. Plasma cells are concentrated in the subepithelial 
layers of the endocervix but substantial numbers are also found in the ectocervix 
and vagina [56]. Unlike other mucosal surfaces such as gastrointestinal and 
respiratory surfaces, where IgA secretion is the dominant isotype, both IgG and 
secretory-IgA (sIgA) are expressed in genital secretions and IgG predominate (see 
section 1.3.3.1).  
1.4.2.4 Cytokines  
Cervical and vaginal epithelial cells are primary source of cytokines comprising IL-
1α, IL-1β, IL-6, IL-7 GM-CSF, M-CSF, TGF-β, CXCL8, CCL3, CCL4, CCL5 and 
CXCL12 [56, 144]. In most cases the secretion of cytokines from epithelial cells 
occurs preferentially towards the apical/luminal compartment resulting in a gradient 
that is important for attracting immune cells to the epithelial surface. For example, 
apically secreted CXCL8 induces neutrophil migration across the epithelium 
suggesting that, in the absence of a chemokine gradient, neutrophils would be less 
likely to cross the epithelial barrier, potentially reducing the level of protective α-
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defensins in luminal secretions. Other cytokines and chemokines such as TGF-β 
are secreted into the basolateral/sub-epithelial compartment where they influence 
the development and function of resident immune cells [124]. 
Many of the above mentioned cytokines can be detected in cervico-vaginal 
secretions and provide important information on inflammatory and immune 
defenses mechanisms in the lower female genital tract [145]. The secretion of 
cytokines leads to rapid communication between the different cell types present in 
the female reproductive tract. Furthermore, these molecules elicit a potent innate 
immune response, which creates an environment hostile to pathogen survival. An 
important cytokine family involved in female reproductive tract immunity, 
particularly against viruses, are the type I interferons [146]. IFNs are rapidly 
induced in the presence of viral and bacterial pathogens, which up-regulate the 
production of hundreds of interferon-stimulated genes (ISGs) via autocrine and 
paracrine actions. Some chemokines are also active antimicrobial compounds, 
being able to directly interfere with microbial pathogenesis. As reported in section 
1.3.3.3.3, CXCL12a and CXCL12b, and the β-chemokines CCL3, CCL4 and CCL5 
may play opposite roles in HIV-1 transmission.  
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1.5 HIV-1 transmission to the FGM 
1.5.1 Current model of HIV-1 transmission to the FGM 
The vaginal mucosa and ectocervix are covered with a multilayered squamous 
epithelium that, if intact, provides a better mechanical protection against HIV-1 
penetration than the single-layer columnar epithelium of the endocervix. Moreover, 
the transformation zone is likely an important site for HIV-1 transmission because 
of its peculiar immunologic features, and all the factors that affect its extension may 
represent important determinants of HIV-1 transmission. However, depending on 
the menstrual cycle and other factors, a barrier of mucus hinders the access of the 
virus to the endocervical epithelium, and the greater extension of the vaginal and 
ectocervical epithelia offers more potential sites for HIV-1 entry (see section 1.4.1). 
Although HIV-1 penetration and infection of the FGT was demonstrated in all 3 of 
these mucosal compartments using different experimental models, the preferential 
site, if any, of HIV-1 transmission in vivo remains unknown.  
1.5.1.1 HIV-1 interaction with the epithelium 
Both free and cell-associated viruses can establish HIV-1 infection in vivo. This 
observation has been confirmed with a number of experimental model, such as 
female macaques infected with SIV, mice infected with HIV, indirectly in humans 
through genetic matching of HIV viruses sequenced from acutely infected women 
and from seminal cells and plasma from their infected partners, and human 
cervical explants studies [41]. 
Initially, some of the deposited seminal cells or free virions are trapped in cervical 
mucus [123, 147]. However, it remains unclear whether this trapping promotes 
transmission by prolonging contact time of infected cells or free virions with the 
mucosa, or whether the trapping impedes transmission by immobilizing the cells 
and virions and increasing their ability to be attacked by innate antiviral 
substances. HIV virions, either inoculated cell free or released from infected donor 
cells, interact with epithelial cells and traverse the epithelium through several ways, 
including transcytosis, endocytosis and subsequent exocytosis, by establishing 
productive infection in epithelial cells, or merely by penetrating through the gaps 
between epithelial cells to encounter its primary target cells (Fig. 1.5.1).  
By using epithelial cells derived from the lower female genital tract, it has been 
demonstrated the binding and entry of HIV-1, and the subsequent ability of HIV-1 
to be transferred to susceptible CD4+ T cells [148]. Another phenomenon that may 
contribute to viral transfer in primary genital epithelial cells is transcytosis [149]. 
During this cellular process, virions in polarized intact epithelial cells can cross 
from the apical to the basal region, where they are released and then can infect 
their primary targets. It has been reported that virions can also productively infect 
the cervical epithelial cells themselves [150], although this remains controversial. 
Conceivably, HIV-1 can also be transported through the cervico-vaginal epithelium 
to the draining lymphatics by donor infected leukocytes. Mechanical 
microabrasions of the mucosal surface induced by intercourse may also allow HIV 
to directly access the target cells at the basal epithelium and the underlying 
stroma. The vaginal epithelium, like squamous epithelia at other sites (eg, skin and 
oral mucosa), is not a structure of uniform thickness. The stromal papillae 
frequently project deep into the outer epithelium, creating considerable variations in 
distance between the luminal surface and the basal membrane (Fig. 1.5.1). 
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Figure 1.5.1 Pathways of HIV-1 invasion in the lower female genital tract mucosa.    
a) Viruses trapped in mucus and penetrating through gaps between epithelial cells. 
b) Infection of intraepithelial lymphocytes. c) Direct import of donor infected cells or 
virions to the mucosal stroma through micro-abrasion of the epithelium.                 
d) Transcytosis. e) HIV-1 interacts with and infects the leukocytes resident in the 
mucosal stroma. f) Infected or virus harboring leukocytes migrate into the draining 
lymphatic and blood vessels. (From Hladik & McElrath, 2008 [42]).   
 
Microabrasions in regions of minimally layered epithelium could more easily 
expose the basal layers of the epithelium or even the underlying stroma. In addition 
to the purely mechanical microabrasions, chemical and infectious alterations of the 
mucosa may open access routes for HIV to reach resident leukocytes (see section 
1.5.2). Regardless of the mode of penetration, studies with SIV in macaques 
indicate that virus crosses the cervico-vaginal epithelium after exposure in vivo 
within 30 to 60 minutes [151]. This penetration may bring the virus in direct contact 
with two cell types that it may infect later: intraepithelial Langerhans cells (LCs) and 
CD4+ T lymphocytes. Interestingly, LCs and, on the stromal side, T cells and 
macrophages  cluster at the tips of the stromal projections into the epithelium , thus 
creating microareas with an increased likelihood of infection. The highly focal 
manner of initial SIV infection in the genital mucosa of macaques in vivo may 
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reflect this notion [120, 123].  
1.5.1.2 HIV-1 target cells in the mucosa 
1.5.1.2.1 Dendritic cells 
It was demonstrated that vaginal intraepithelial LCs are susceptible to HIV-1 entry 
and infection, either in macaques infected with SIV and in a model of human 
vaginal epithelial sheets, separated from the underlying stroma, infected and 
cultured ex vivo [119, 151]. The latter study demonstrated that vaginal LCs very 
efficiently internalize HIV-1 into cytoplasmic organelles and, when the cells 
subsequently exit the epithelium at the basal side, they can take intact virions with 
them. Vaginal LCs express CD4, CCR5 and the C-type lectin langerin, but not 
CXCR4 and another C-type lectin, DC-SIGN (see section 1.4.2.2.1) [152]. In 
contrast to vaginal LCs, HIV is efficiently captured by langerin in epidermal LCs 
[153]. Upon viral entry, langerin directs HIV-1 to Birbeck granules, where the virus 
is degraded. It has been propose that in vaginal LCs, HIV may bypass C-type 
lectins, including langerin, in favor of other routes of binding and endocytosis, 
allowing the virus to reach endocytic compartments that are less hostile to the virus 
than the Birbeck granules, although no productive HIV-1 infection of vaginal LCs 
has been reported [119].  
In addition to LCs, DC-SIGN expressing DCs are present in the stroma of the 
FGM. HIV-1 has been reported to exploit the binding to DC-SIGN to directly infect 
DCs that may transmit the virus to CD4+ T cells [154]. Of note, recent studies 
suggest that the role of DC-SIGN in promoting the spreading of HIV-1 is not only 
related to the ability of recognizing and attaching the virus to the DC surface. 
Binding to DC-SIGN also triggers a signaling pathway mediated by Raf-1 that is 
required for the generation of full-length viral transcripts and HIV-1 replication in 
DCs [155].  
1.5.1.2.2 CD4+ T cells 
The lamina propria of the lower human FGT contains many CD4+ T cells, which are 
often enriched in the superficial stroma, close to the basal membrane. CD4+ T cells 
also infiltrate the vaginal and ectocervical squamous epithelium. The majority of 
these cells are effector memory T cells that express higher levels of CCR5 than 
those circulating in blood [143]. Investigators using human organ cultures of 
vaginal, ectocervical, and endocervical tissues, and SIV challenge experiments in 
macaques consistently found high numbers of CD4+ T cells that were infected with 
HIV-1 early after virus exposure [120, 156, 157]. Interestingly, SIV productively 
infects not only activated (HLA-DR+ Ki67+) T cells but also resting (HLA-DR− Ki67−) 
T cells [157]. Although it is impossible to selectively remove DCs from the epithelial 
sheets, several lines of evidence indicate that initial infection of intraepithelial CD4+ 
T cells is not dependent on DC-mediated viral uptake and infection in trans [119].  
1.5.1.2.3 Macrophages 
According to some human explant studies, macrophages in the cervico-vaginal 
stroma were also identified as targets for HIV-1 infection [158-160]. However, 
immunostaining studies have never conclusively demonstrated that macrophages 
in the human uterine cervix or the vagina express CCR5 in situ. In contrast to 
experiments in the human explant model, vaginal SIV challenge experiments in 
macaques either rarely revealed SIV-infected macrophages in genital tissues or 
failed to detect them at all [151, 157]. Captured HIV can be archived within 
macrophages for several days and still be transmitted to T cells. Therefore, the role 
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of macrophages in early HIV-1 infection of the lower genital tract in women still 
needs to be defined. 
1.5.1.3 Early events in HIV-1 transmission 
Although there is some argument on the phenotype of the first cell populations that 
are productively infected in the female genital submucosa, HIV-1 may take 
advantage of multiple cellular targets to establish infection. Once the virus gains 
access to the host, the appearance of viral spread within the submucosae of the 
FGT is not typically demonstrable until 3-4 days after exposure of NHPs to a high 
dose of virus [123]. Infection then expands locally before detection of infection in 
the draining lymph nodes and systemically throughout the secondary lymphoid 
organs (Fig. 1.5.2).  
 
 
Figure 1.5.2 Major events in vaginal transmission of HIV-1. Within hours, virus may 
gain access through breaks in the mucosal epithelial barrier to susceptible target 
cells. The small focal infected founder population expands locally in ‘resting’ and in 
activated CD4+ T cells. Local expansion is necessary to disseminate infection to 
the draining lymph node, and subsequently through the bloodstream to establish a 
self-propagating infection in secondary lymphoid organs. GALT = gut-associated 
lymphoid tissue. (From Haase, 2010 [161]).  
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Some groups have demonstrated the presence of both SIV or infected cells within 
the genital draining lymph nodes, albeit at very low levels, shortly after intravaginal 
SIV challenge, suggesting that rapid dissemination to lymphatic tissues can occur 
after mucosal exposure [123, 151]. However, there is little evidence of active viral 
replication in draining or systemic lymphatic tissues until 5-6 days after vaginal 
challenge. Apparently, although viral particles themselves might rapidly gain 
access to draining lymphatic tissues after intravaginal SIV inoculation through 
lymphatic drainage or carried by DCs, the threshold for a self-propagating infection 
is not crossed until virus and infected cells are produced locally in sufficient 
quantities to establish infection distal to the portal of entry, because the draining 
lymph nodes are not the site where productive infection is first detected [157]. 
Thus, dilution, trapping in cervical mucus, the physical mucosal epithelial barrier 
and other mechanisms transform exposure to a large quantity of virus in the 
inoculum to a small founder population of infected cells that must then expand 
locally for a few days before systemic infection is established [161] (Fig. 1.5.2). The 
‘eclipse’ phase observed in humans between presumptive exposure and 
development of either detectable viremia or clinically apparent symptoms of an 
acute viral syndrome, and data showing increased HIV-1 incidence with sexually 
transmitted co-infections (see section 1.5.2), support the notion of a requirement 
for a “threshold” level of mucosal susceptible CD4+ target cells to establish local 
infection. This CD4+ target cells can result from active recruitment to mucosal 
tissues through early host inflammatory processes or as a result of preexisting 
inflammation. In this picture, DCs and macrophages in the FGM may play a key 
role in maintaining HIV in an infectious state until the arrival of activated CD4+ T 
cells within the submucosa (see section 1.5.1.2).  
1.5.1.4 The transmitted virus 
One of the greatest obstacles in preventing HIV transmission is the enormous 
sequence diversity both within an individual and globally. However, during 
transmission this considerable diversity is reduced because the infecting virus 
undergoes a genetic bottleneck that results from the biology of mucosal 
transmission [162]. Recently developed methods for viral sequence analysis, often 
designated as single-genome amplification (SGA), have both documented and 
permitted a greater understanding of the genetic restriction during sexual 
transmission of HIV. It was discovered in cohorts self-identified as heterosexual 
that the number of transmitted variants can be traced back to a single founder 
variant in roughly 80% of infections [163]. To date, transmitted Envs have all been 
shown to be functional and capable of mediating entry via CD4, using CCR5 as the 
coreceptor in most cases. Furthermore, when full-length transmitted/founder 
viruses were cloned, each showed significant replication in CD4+ T cells but did not 
replicate in monocyte-derived macrophages [164], findings that are consistent with 
CD4+ T cells being identified as the earliest productively infected cell type in vivo in 
NHP studies and ex vivo in human tissues (see section 1.5.1.2.2). 
In a recent study HIV-1 transmission to human cervical explants was evaluated 
comparing 6 chronic isolates and 2 transmitted/founder viruses and no difference 
in efficiency of transmission was observed between the two groups of viruses 
[165]. Interestingly, despite CD4+ T cells resident in the FGM display high levels of 
expression of CCR5 as well as CXCR4, human cervico-vaginal explants infected 
ex vivo with HIV-1 preferentially support R5 variant productive replication [143]. 
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These data suggest that the bottleneck observed in vivo may be more complex 
than a simple selection and transmission of one or few HIV variants, and rely on 
determinants other than viral genetic features and restriction factors in the FGT.    
1.5.2 Determinants of the efficiency of HIV-1 transmission to the FGM 
1.5.2.1 Host susceptibility 
The efficiency of HIV-1 transmission across the mucosa is a function of both 
recipient susceptibility and donor infectiousness. Recipient susceptibility to HIV-1 is 
influenced by the mucosal integrity, availability of susceptible cells, and 
environmental and behavioral factors. As discussed in section 1.5.1, mucosal 
trauma during heterosexual contact may disrupt the epithelial barrier and provide 
HIV-1 direct access to the microcirculation of the mucosa and to the target cells 
resident in the lamina propria. Behavioral factors, such as increased frequency of 
sexual contacts, are associated with increased HIV-1 transmission [59]. 
1.5.2.1.1 Pre-existing infections and genital microflora 
The integrity of the genital epithelium may be compromised by pre-existing 
sexually transmitted infections, that can also facilitate the recruitment and 
activation of immune cells in the genital submucosa, increasing the number of 
potential HIV-1 target and fueling the expasion of the local pool of infected cells 
[166]. Mucosal infections associated with increased susceptibility include 
chancroid, syphilis, herpes simplex virus (HSV) infection, and undiagnosed genital 
ulcers. Local infections may also enhance recipent susceptibility to HIV-1 infection 
by disrupting the natural equilibrium existing between FGM and commensal 
microflora [56]. For example, the acidic microenvironment of the vagina is 
maintained by lactic acid producing commensal bacteria, such as Lactobacillus 
[167]. A higher pH in some ethnic groups correlates with a higher proportion of 
anaerobic bacteria present in the vagina. In addition to regulating vaginal pH, a 
recent study by Ahmed et al. reported that specific commensal microdomes may 
affect HIV transmission by selective activation of TLR signaling pathways [139]. 
This concept requires further research but is an important observation on how 
commensal bacteria may directly alter the vaginal environment thus mediating 
infection. Moreover, it was reported that the amount, molecular size and 
morphology of mucin glycoproteins protecting the genital epithelium can be altered 
in disease states. Lactobacillus organisms that colonize the normal human vagina 
can stimulate the expression of mucins (MUC 2 and 3), whereas pathogens 
associated with bacterial vaginosis are capable of degrading cervicovaginal mucus, 
facilitating HIV-1 penetration to reach the mucosa [56]. 
1.5.2.1.2 Menstrual cycle 
The FGM displays unique characteristics compared to other mucosal sites 
because in addition to protecting against pathogens, it must adapt to a spectrum of 
physiologic events that include fertilization, implantation, pregnancy and parturition. 
For this purposes, the menstrual cycle ensures a strict control of tissue growth and 
remodeling as well as of the immune defenses of the genital mucosa [168]. By 
examining multiple immunological parameters Wira and Fahey concluded that 
within the FGT during a normal menstrual cycle, there is a period lasting 7–10 days 
when important components of innate, humoral, and cell-mediated immunity are 
suppressed by estradiol and/or progesterone, enhancing the potential for HIV-1 
infection [169]. The onset of this ‘‘window of vulnerability’’ coincides with an 
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increase in estradiol at about the time of ovulation (Fig. 1.5.3).  
 
 
 
Figure 1.5.3 Relative changes in levels of estradiol and progesterone 
during the proliferative and secretory stages of the menstrual cycle. Indicated on 
days 14-23 is the window of vulnerability to HIV infection. FSH = follicle stimulating 
hormone; LH = luteinizing hormone. (From Wira & Fahey, 2008 [169]). 
 
Analysis of the concentrations of cytokines, chemokines, and antimicrobials in 
cervico-vaginal lavage indicated that SLPI, defensins, and lactoferrin dropped 
significantly at midcycle (day 13) and remained depressed for 7–10 days, returning 
to proliferative stage levels just before menstruation [170]. It was also showed that 
the titers of anti-human papillomavirus 16 virus-like particle IgG in cervical 
secretions dropped approximately nine-fold at midcycle during ovulatory cycles 
[171]. It remains unclear whether sex hormones act directly on immune cells and 
their secretions in the lower FGT, or whether changes are due to alterations in 
mucus content or volume. Finally, it has been demonstrated that the immune 
system throughout the FGT is dampened at the time of fertilization to optimize 
conditions for implantation and pregnancy [124]. During the proliferative (estradiol-
dominant) phase of the menstrual cycle leading up to ovulation, expansion of 
CD25+ Foxp3+ regulatory T cells occurs in the human uterus. This coincides with a 
decrease in cytolytic activity by uterine CD8+ cells after ovulation in the uterus. 
Thus, the modulation of innate and adaptive immune defenses in the FGT by 
sexual hormones may produce a particular status of immunity aimed to establish 
tolerance to the fetus, although this enhances host susceptibility to infection of HIV-
1 and other sexually transmitted pathogens.   
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1.5.2.2 Donor infectiousness 
Donor infectiousness reflects the probability that the donor will transmit HIV-1 
infection to the recipient. The infectiousness of a donor is greatest during primary 
and late-stage HIV-1 infection, when blood levels of virus are maximal [59]. A high 
viral burden in blood is a key predictor of heterosexual transmission and appears to 
correlate directly with the level of virus in genital secretions and, consequently, the 
amount of virus inoculated onto a mucosal surface [172]. Increases in the genital 
viral load have great impact on the rates of sexual transmission. Using a 
probabilistic empirical model that accounts for semen viral load and the number of 
cervical CCR5 receptors, the probability of transmission was 3 per 10,000 
episodes of intercourse when the semen viral load was 1,000 copies per ejaculate, 
but 1 in 100 when the semen contained 100,000 viral copies per ejaculate [173] 
(Fig. 1.5.4). The concept that viral shedding in genital fluids reflects the plasma 
viral load is furthered by findings that successful ART decreases the viral load in 
semen. However, some men with undetectable plasma viral loads shed HIV in their 
semen, and the compartmentalization of HIV-1 infection in the male genital tract 
results in the presence of viral variants in semen that are different from the ones 
detectable systemically (see section 1.3.5). These considerations highlight the 
importance of the intrinsic characteristics of semen and local factors restricted to 
the male genital tract of HIV-1-infected individuals as determinants of the efficiency 
of HIV-1 sexual transmission. Our lack in the understanding of such phenomenon 
largely depends on the fact that a model suitable for the study of seminal factors 
under controlled laboratory conditions has yet to be developed. 
 
 
 
Figure 1.5.4 Estimated male-to-female per sexual contact HIV-1 
transmission probability based on the load of HIV-1 in semen and CCR5 density  
on CD4+ T cells resident in the female genital mucosa. (From Cohen, 2006 [174]).  
 	  	  
	  	   41	   	  
	  
1.5.2.2.1 Infections of the MGT 
HIV-1 infection induces the disruption of the equilibrium between a human host and 
its virome, leading to two grave consequences: reactivation of ubiquitous symbiotic 
viruses, which start to replicate to higher levels, and infection by new viruses [175]. 
Male genital tract infections and local inflammation increase donor infectiousness, 
likely because of increased HIV-1 shedding and increased accumulation of virus-
bearing cells [59, 166]. Sexually transmitted diseases (STDs) that cause ulcers 
generally increase shedding of HIV in the genital tract [176]. This can occur by 
direct shedding of HIV from the ulcerative lesion. As the most common causative 
agent of genital ulcer diseases worldwide, HSV has an important role in HIV 
infections. HIV-1 RNA was detected in ulcer swabs in 25 of 26 men with 
symptomatic HSV-2 infection, and the levels exceeded 10,000 copies/mL of swab 
sample in most cases [177]. Even asymptomatic HSV shedding was found to be 
associated with increased HIV-1 shedding. In general, STDs that cause 
inflammation increase the concentration of HIV-1 in the urethra and semen [166]. 
Treatment of STDs reduces the concentration of HIV-1 in genital secretions [178]. 
A modest number of experiments have been conducted in vitro to examine the 
direct effect of various sexually transmitted pathogens on HIV replication. Co-
infection of macrophages with HIV-1 and certain opportunistic pathogens, such as 
Mycobacterium avium or cytomegalovirus (CMV), causes bidirectional up-
regulation of both HIV-1 and the pathogen [59]. Infection of macrophages with 
opportunistic pathogens may also induce cytokines, such as TNF-α, that enhance 
HIV-1 replication, and CCR5 ligands, such as CCL3 and CCL4, as well as other 
chemokines that can recruit mucosal HIV-1 target cells at the site of transmission 
[59].  
Ping and colleagues conducted a detailed study of viral diversity in variants that 
were harvested from the semen of HIV-1 infected men before and after 
antibacterial therapy for STDs [179]. The results showed that three-quarters of both 
STDs and control subjects had multiple HIV variants in their blood, with even more 
variability in semen. Subjects with STDs who received treatment had more 
changes in semen variants than blood variants at follow-up, showing that local 
genital conditions were affecting viral diversity in semen in a way that was not 
reflected in blood. 
1.5.2.2.2 Human herpesviruses 
Due to their ubiquity in the human population, human herpesviruses (HHVs) are 
among the most common viruses that undergo reactivation in HIV-1-infected 
patients [180]. Human herpesviruses can cause lytic, persistent, and 
latent/recurrent infections, and Epstein-Barr virus (EBV or HHV-4) and HHV-8 are 
associated with cancers. Once a patient has become infected by a herpesvirus, the 
infection remains for life. The initial infection may be followed by latency with 
subsequent reactivation. Although these viruses usually cause benign disease, 
they can also cause significant morbidity and mortality, especially in 
immunosuppressed people [34]. 
There are at least 25 viruses in the family Herpesviridae (currently divided into 
three sub-families). 8 herpesvirus types are known to infect man frequently (Table 
1.5.1).  
 
 
	  	   42	   	  
	  
Virus Primary Target Cell 
Site of 
Latency Means of Spread 
Herpes simplex 
type 1 (HHV-1) 
Mucoepithelial 
cells Neuron Close contact 
Herpes simplex 
type 2 (HHV-2) 
Mucoepithelial 
cells Neuron 
Close contact 
(sexually 
transmitted 
disease) 
Varicella-zoster 
virus (HHV-3) 
Mucoepithelial 
and T cells Neuron 
Respiratory and 
close contact 
Epstein-Barr 
virus (HHV-4) 
B cells and 
epithelial cells B cell 
Saliva (kissing 
disease) 
Kaposi 
sarcoma–related 
virus (HHV-8) 
Lymphocyte 
and other cells B cell 
Close contact 
(sexual), saliva ? 
Cytomegalovirus 
(HHV-5) 
Monocyte, 
lymphocyte, 
and epithelial 
cells 
Monocyte, 
lymphocyte, 
and ? 
Close contact, 
transfusions, 
tissue transplant, 
and congenital 
Herpes 
lymphotropic 
virus (HHV-6) 
Like CMV, 
salivary glands, 
neurons 
T cells and 
? Saliva 
Human 
herpesvirus 7 
(HHV-7) 
Like CMV T cells and ? Saliva 
 
Table 1.5.1 Human herpesviruses classified by their target cells and location in the 
latent state. (From Murray et al., 2008 [34]). 
 
HSV-1, HSV-2 and CMV are sexually transmitted pathogens and are extremely 
prevalent worldwide. Among HIV-1-infected people the seroprevalence of HSV-2  
is ~70 to 90% [181], and seminal shedding of HSV is associated with higher HIV-1 
RNA genital levels (see section 1.5.2.2.1). The effect of HSV infection on the viral 
burden of HIV in blood has been the subject of unresolved but important debate 
about the adjunctive potential of HSV antiviral therapy on the management of HIV. 
It was demonstrated that anti-herpetic therapy in individuals who are co-infected 
with HIV and HSV-2 reduced HIV blood and seminal plasma viral loads [182, 183]. 
However, a clinical trial  conducted by Celum at al. showed that daily acyclovir 
therapy did not reduce the risk of transmission of HIV-1, despite a reduction in 
plasma HIV-1 RNA and a 73% reduction in the occurrence of genital ulcers due to 
HSV-2 [184]. 
The seroprevalence of CMV among HIV-infected men is even higher at 95 to 
100%, and CMV is associated with HIV disease progression in both treated and 
untreated individuals [185]. A possible mechanism for this accelerated disease 
progression may be CMV enhancement of HIV replication, especially in the male 
genital tract, where CMV levels positively correlate with HIV levels [186]. Moreover, 
asymptomatic CMV coinfection is associated with higher T cell immune activation, 
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which is linked to blunted CD4+ T cell recovery during antiretroviral therapy and to 
premature mortality [187].  
Compartmentalized replication of CMV in the genital tract, probably has 
consequences for CMV transmission, impacts localized immune responses and 
interacts with other sexually transmitted viruses, like HIV-1 [188]. Except for HSV-2 
and CMV, limited information is available on herpersvirus infections in the male 
genital tract of HIV-1-infected individuals and their shedding in semen. 
Human herpesviruses have been studied mainly in the context of disease 
progression. Many mechanisms have been reported through which herpesviruses 
contribute or interfere with HIV-1 replication. The strategies used by these viruses 
to evade the host immune response include: (1) downregulation of HLA (e.g., by 
CMV-encoded US2, 3, 6, and 11; HHV-6- and HHV-7-encoded UL-21); (2) 
induction of host cytokines (e.g., of CXCL8, CCL5, CCL2, and IL-1 by CMV or 
EBV); (3) interference with host cytokine signaling (e.g., TNF-α- and IFN-α-
signaling modulated by EBV); (4) expression of virus-encoded chemokine 
homologs (virokines) and chemokine receptors (viroceptors) (e.g., EBV-encoded 
IL-10 homolog BCRF1, CMV-encoded IL-10 homolog US111, HHV-6-encoded 
CCL5 homolog U83, and HHV-7-encoded β-chemokine receptor homolog U12); (5) 
inhibition of apoptosis (e.g., by CMV-encoded v-Bcl-2 homolog or EBV-encoded v-
ICA and v-MIA); and (6) altered activation of autologous complement (e.g., by 
modulation of CD46 expression by HHV-6 and HHV-7) [175]. All these effects may 
favor the immune evasion not only of these viruses, but also of HIV-1 itself.  
On the other hand, some of the effects induced by HHV-6 and HHV-7 have been 
demonstrated to inhibit HIV-1 replication. Up-regulation of CCR5-binding 
chemokines CCL3, CCL4, and CCL5 was showed to mediate HIV-1 suppression 
by HHV-6 in co-infected human lymphoid tissue ex vivo [189], although a 
prolonged up-regulation of CCR5-binding chemokines in vivo favours the selection 
for CCL5-resistant viral variants [190]. CCL5 resistance, including the emergence 
of highly pathogenic CXCR4-utilizing HIV-1 variants, is associated with the late 
stages of HIV disease [191]. This association may explain how HHV-6, in spite of 
the ability to suppress HIV-1 infection, constitutes a co-factor in HIV disease 
progression [192]. A diminished CD4 expression has been reported for HHV-7 
infection of human lymphoid tissues ex vivo. In these tissues, CD4 is down-
regulated not only in HHV-7-infected cells, but also in bystander (uninfected) CD4+ 
T cells, making this effect massive. As a result, in HHV-7-coinfected human 
tissues, HIV-1 is suppressed [193].  
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1.6 Study models of HIV-1 transmission to the FGM 
Understanding the mechanisms of HIV-1 transmission to the FGM requires 
knowledge of the functions and interactions of all immune cells and of the 
extracellular matrix in this tissue. Although conventional cultures of isolated cell 
lines or peripheral blood mononuclear cells have been useful in many areas of HIV 
research, these cultures are limited by the fact that they do not reproduce the 
spatial distribution of cells and their native communication within the tissue 
cytoarchitecture.  
1.6.1 Non human primates 
Experimental SIV infections of rhesus macaques have been used for decades to 
study the various aspects of the biology of primate lentivirus infection. Many 
aspects of human infection can be recapitulated in a NHP model. These models 
provide a unique opportunity to study early events in viral transmission and 
evolution, both systemically and within tissue compartments. The ability to sample 
tissues before infection and immediately after challenge make NHP models a 
valuable tool for helping to elucidate the contributions of different anatomical 
barriers and innate immune mechanisms to prevent infection.  
Historically, the initial development of NHP models involved the identification of 
pathogenic viral isolates and the use of high-dose intravenous inoculation to 
reproducibly infect the animals, cause viremia typical of human infection, and 
eventually lead to AIDS-like pathology. Next, a high-dose intrarectal challenge 
model was adopted for basic transmission and vaccine efficacy studies designed to 
achieve 100% infection rate while providing a relevant mucosal route of infection of 
broader clinical relevance. Mucosal challenge models were further modified with a 
shift to repeated challenges with lower inocula, titered to more accurately simulate 
clinically relevant virus exposures [194]. 
Studies of vaginal infections in NHP models have been problematic because of the 
extensive inte-animal variability in establishing infection, even after uniform 
challenge conditions. Factors contributing to this variability may include changes in 
epithelial thickness and mucus that vary as a function of menstrual cycle stage, 
access point of the virus, preexisting inflammation, or target cell availability. Finally, 
although it has been reported that cell-associated virus can also initiate infection 
[195], it is difficult to rigorously rule out the potential contributions to transmission of 
cell-free virus derived from freshly produced virus even in thoroughly washed 
inoculums of infected cells. Although it is thus difficult to unequivocally demonstrate 
a role for infected cells in mucosal transmission, it is unequivocally clear that cell-
free SIV is sufficient in these models to recapitulate the infection outcomes 
observed in HIV infection.  
1.6.2 Human tissue explants 
Typically, tissue fidelity and function are best achieved by attempts to maintain 
tissue biopsies or explants ex vivo, rather than attempts to reconstruct tissue from 
individual cell types. For the study of multiple aspects of HIV pathogenesis our 
laboratory has favored the use of raft culture, in which blocks of human tissue are 
cultured on collagen sponges at the air-liquid interface. This ex vivo raft model of 
tissue culture is based on work of Joseph Leighton [196, 197]. Leighton’s three-
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dimensional histoculture method, which utilized a sponge matrix, was further 
developed in the 1980s by Robert Hoffman and his colleagues for anticancer drug 
studies [198]. Our laboratory first benchmarked this method for HIV studies using 
cultures of human tonsils and lymph nodes [199]. 
This model has many advantages (Tab. 1.6), the first of which is the preservation 
of the tissue architecture for 2–3 weeks. Certain functions of the lymphoid tissue 
are also maintained ex vivo, including the ability to release a spectrum of cytokines 
similar to those released by in vivo tissue, and the ability of tissue challenged with 
recall antigens (tetanus or diphtheria toxoids) to respond by producing specific 
antibodies [200]. Ex vivo tissues support HIV replication without the exogenous 
stimulation that is necessary for productive HIV infection in isolated lymphocytes. 
Also, these tissues support replication of other human viruses including HHV-6 
[189, 201], HHV-7 [193], CMV [202], HSV-2 [203], vaccinia [204], measles virus 
[205, 206], and West Nile virus [207], as well as non-viral human pathogens such 
as the bacterium Borrelia burgdorferi [208] and the parasite Toxoplasma gondii 
[209]. Some of these viral and non-viral pathogens are commonly associated with 
HIV-1, thus allowing the simultaneous study of HIV co-pathogenesis.  
Recently this ex vivo tissue system was extended to include cultures of cervico-
vaginal and rectosigmoid tissues. Since these tissues serve as the first gateway for 
HIV-1 sexual transmission, preserving the specific mucosal cell phenotypes and 
functions are critical for understanding early events in HIV-1 transmission. 
Moreover, cervico-vaginal, rectosigmoidal, and other ex vivo tissues can be used 
to evaluate potential microbicides in pre-clinical tests. 
Advantages Disadvantages 
• Preservation of tissue 
cytoarchitecture, including major 
lymphocyte subtypes and follicular-
dendritic cell network 
• In vivo-like spectrum of cytokine 
release 
• Continuous expression of HIV 
coreceptors over 2 weeks in culture 
• Support of HIV replication without 
exogenous stimulation or activation 
• 'In vivo pattern of replication': HIV 
replicates in both activated and 
nonactivated cells 
• Other tested human viruses, bacteria 
and parasites readily infect tissues, 
allowing the study of their 
pathogenesis and interactions 
• Viral movement in the tissue can be 
followed in real time by confocal 
microscopy 
• Tissues start to deteriorate after 3 
weeks in culture 
• Difficulty in monitoring cells beyond 
the depth of confocal microscopy 
(unless cells are isolated for 
analysis) 
• The system does not reflect the 
effects of in vivo systemic factors 
• Labor: multiple blocks of tissue are 
required for every experimental 
condition to overcome tissue 
heterogeneity 
• Donor-to-donor variability 
Table 1.6. Advantages and disadvantages of human tissue ex vivo model 
for the study of human pathogens. (From Grivel & Margolis, 2009 [210]). 
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1.6.2.1  Cervico-vaginal models to study HIV-1 infection 
Cervical explant cultures were first developed by Fink et al. for the study of 
epithelium metaplasia in vitro [211]. They consisted of large tissue explants 
cultured on a thin slab of agarose-gelled serum-free Eagle’s Basal Medium on top 
of a stainless steel supporting grid. This culture system was successfully adapted 
to the study of HSV-2 and HSV-1 infection in vitro and was shown to support the 
replication of these two human herpesviruses [212]. O’Brien et al. modified this 
method for the study of the production of glycoprotein from normal and malignant 
cervical explants of smaller size cultured either fully immersed in serum-free 
culture medium or maintained at the air-liquid interface, supported only by a 
stainless steel grid mesh [213]. On the basis of glycoprotein production, the 
authors concluded that the grid technique was superior to the immersion culture. It 
was this grid technique which was adapted to the study of HIV-1 infection in human 
cervical explants by Palacio et al. [214]. In this method, cervical explants (3×3×2 
mm) were infected by immersion in viral stocks, washed twice to remove 
unadsorbed virus, and then supported on a stainless steel mesh at the air-liquid 
interface. In contrast to some NHP studies, where the first cells productively 
infected by HIV-1 are CD4+ T cells (see section 1.5.1), in this ex vivo model the 
majority of viral antigen was detected in sub-epithelial cells expressing markers of 
macrophages, isolated from tissues infected with HIV-1 R5 variants. This can be 
explained considering that infection of explants by soaking in cell-free virus 
suspension gives the virus full access to both epithelial and subepithelial cells, thus 
mimicking viral penetration through a damaged epithelium. To study the ability of 
HIV to cross a continuous layer of genital epithelium, explants have to be polarized 
in an Ussing chamber mechanically sealed with rubber O rings [160]. In such a 
system, the tightness of the seal is a critical issue and has to be constantly 
controlled, as monitored for example from the lack of permeability to a small tracer 
molecule, such as inulin. Such experiments demonstrated that intact epithelium is 
impervious to cell-free and to cell-associated HIV-1 penetration. This result was at 
variance with results obtained in a polarized and sealed cervical explant model, in 
which a rapid penetration of HIV through the epithelial layer was reported [158]. In 
the latter model, circular explants obtained by punch biopsies were cultured, 
epithelium pointing upward, on the upper chamber of a transwell and sealed with 
agarose. Production or transfer of virus was detected from the infection of indicator 
cell lines placed in the lower chamber, mimicking the basolateral submucosa. An 
alternative way to maintain cervico-vaginal explants is to culture them on rafts 
rather than immersed in culture medium [147].  Essentially, this is an adaptation to 
cervico-vaginal tissues of the collagen raft culture model initially developed for 
tonsils in our laboratory [199]. This adaptation consisted in immersing explants in 
viral stocks, transferring them on top of collagen sponges, and culturing them at 
the air-liquid interface. Aside from their culture methods, this and the models 
described above differ by the way in which HIV-1 infection is detected. A 
productive infection in the immersion models, whether they involve explants 
containing the whole mucosal layer or only epithelial sheets [119], relies on the 
infection and viral amplification by the cells that populate the explants. In the 
polarized models, HIV-1 infection depends the transfer of virus to indicator cell 
lines. 
While each of these systems has its intrinsic limitations, they have all proven to be 
valuable tools for studying several aspects of HIV-1 infection in the lower female 
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genital tract. These models have been widely used as platforms to test potential 
microbicides [159, 215-218] and viral fitness [219]. Obviously, none of these 
models fully reproduces the complex phenomenon of HIV-1 transmission, and 
explant models suffer from the limitation that the tissue is disconnected from the 
body and its supply of cells, especially of immune cells, which may be recruited to 
the genital tract upon infection and fuel the initial pool of infected cells in vivo. 
However, we consider this model adequate for the study and characterization of 
the very early events in HIV-1 infection. 
1.6.2.1.1 Optimization of the raft-based histoculture  
In spite of their peculiar advantages, neither of the two main culture methods 
(polarized or immersion/raft) addressed the nature of the HIV-infected cells by use 
of polychromatic flow cytometry in the absence of cell activation. In an attempt to 
improve these models, we have developed an explant culture model built on the 
collagen sponge raft culture system (Fig. 1.6). In this model, small blocks of 
cervical tissue mucosa are infected by immersion in viral stock for 2 hours, washed 
extensively, and cultured on top of collagen sponge gel in RPMI supplemented with 
10% FBS in the absence of cellular activators (see section 2.4.2). To account for 
tissue variation due to sampling, at least 16 explants are used per experimental 
condition. Donor-matched explant cultures containing potent antiviral agents are 
used to control for viral adsorption during infection and subsequent desorption 
during culture.   
To apply the power of polychromatic flow cytometry to characterize the cells 
infected in explants, it is required to prepare a single-cell suspension of tissue 
cells. Although mechanical digestion has been used by other groups [156], it is our 
experience that such a treatment results in poor cell recovery because of cell death 
during tissue processing. Instead, we have developed an enzymatic digestion 
protocol, which spares most of the cell surface markers studied [210]. The first 
application of this new method of cervical explant culture and analysis was 
reported by Saba et al. [143]. This study established that the majority of cervical T 
cells are effector memory cells. Moreover, as in vivo, in spite of the broad 
expression of CXCR4, explants preferentially supported replication of R5 rather 
than X4 HIV-1 variants. Because this model does not involve the use of cellular 
activators, it was possible to characterize the cells isolated from infected explants: 
R5 HIV-1 infection occurred preferentially in activated CD38+ CD4+ T cells and was 
followed by activation of bystander CD4+ T cells. The same culture model was 
employed in the present work to address the effect of seminal interleukin-7 on HIV-
1 transmission to cervico-vaginal tissue explants. 
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Figure 1.6 Preparation of cervico-vaginal tissue for histoculture. Note the difference 
in color between ectocervix and endocervix,  
which both appear shiner compared to muscular tissue 
 due to the presence of a layer of mucus covering the epithelium. 
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2. MATERIALS AND METHODS 
2.1 Ethics statement and source of clinical samples 
The protocol was approved by the Institutional Review Board of both the National 
Institutes of Health and the All India Institute of Medical Sciences (AIIMS), New 
Delhi, India. The study participants were recruited in AIIMS between September 
2008 and November 2009 (Table 2.1). After 2–5 days of sexual abstinence, semen 
samples were obtained by masturbation into a sterile container and processed 
within 1 hour of ejaculation. Semen was centrifuged at 800×g for 10 min, and the 
resulting supernatant (seminal plasma) was aliquoted and stored at -80 °C until 
use. 84 therapy-naïve HIV-infected patients were enrolled in the study; one patient 
was excluded from further analysis because he was infected with HIV-2. Due to the 
social and cultural stigma for HIV-1 infection in India few of the enrolled patients 
missed follow up visits, thus sufficient material to measure HIV-1 blood plasma 
load was available from 74 individuals; paired HIV-1 load and CD4+ T cell counts 
were available from 70 individuals. Semen was collected from 50 HIV-1-infected 
individuals; paired blood and seminal plasma samples were available from 43 of 
these. 33 HIV-1-uninfected individuals, among healthy volunteers referred to the 
AIIMS fertility clinic, were enrolled in the study as HIV-1-uninfected controls. Blood 
and semen were collected from 27 and 28 individuals respectively; paired blood 
and seminal plasma samples were available from 22 HIV-1-uninfected controls.  
Tonsils from routine tonsillectomies were obtained from the Children’s Hospital 
(Washington, DC). Cervico-vaginal tissues were obtained from routine 
hysterectomy through the National Disease Research Interchange (NDRI, 
Philadelphia, PA). All tissues were obtained according to an Institutional Review 
Board-approved protocol. 
  HIV-1 + 
(n=83) 
HIV-1 – 
(n=33) 
  Number  
(frequency %) 
Age 
< 30 years 23 (27) 14 (42) 
> 30 years 60 (73) 19 (58) 
Marital 
status 
unmarried 19 (23) 0 
married/long term consensual relation 64 (77) 33 (100) 
Employment 
status 
unemployed 9 (11) 0 
self-employed 44 (53) 14 (42) 
full-time wage earner 30 (36) 19 (58) 
Mode of   
HIV-1 
acquisition 
heterosexual intercourse 70 (84.3) NA 
injection drug use/transfusion related 5 (6) NA 
males who have sex with males 6 (7.2 NA 
unknown 2 (2.5) NA 
  
Table 2.1 Socio-demographic characteristics of the enrolled HIV-1-infected and 
HIV-uninfected individuals. NA = not applicable. 
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2.2 Nucleic acid extraction and real-time PCR 
Nucleic acids were extracted from seminal and blood plasma with the NucliSENS 
Biomerieux EasyMag 2.0 instrument (BioMerieux, Durham, NC) according to the 
manufacturer’s instructions. 200 µL of sample were placed in a disposable vessel 
and then loaded onto the extractor instrument. After 10 min of intial lysis 
incubation, 150 µL of magnetic silica was added to each sample. The samples 
were then processed according to the manufacturer’s instructions. Purified nucleic 
acid were eluted and stored at -80°C until further use. 
To measure the viral loads of human herpesviruses (HHV) we employed a real-
time PCR TaqMan assay using the sets of primers and probes listed in table 2.2. 
 
Target 
gene Forward primer Reverse primer Probe (FAM) 
HSV-2 
UL27 cgcatcaagaccacctcctc gctcgcaccacgcga cggcgatgcgccccag 
EBV 
EBNA gactgtgtgcagctttgacgat cagccccttccaccataggt cctccctggtttcc 
CMV 
UL83 tcgcgcccgaagagg cggccggattgtggatt caccgaacgaggattccgacaacgt 
HHV-6 
UL67 cgctaggttgaggatgatcga caaagccaaattatccagagcg cccgaaggaataacgctc 
HHV-7 
UL67 agcggtacctgtaaaatcatcca aacagaaacgccacctcgat gagaacatcgctctaactggatca 
HHV-8 
ORF26 gtccagacgatatgtgcgc actccaaaatatcggccgg ttggtggtatatagatcaagttc 
 
Table 2.2 Primers and probes used in the quantification of human herpesvirus 
target genes by real-time PCR.  
 
Amplifications were performed in 25 µl reaction mixture containing 1X Fast 
TaqMan PCR master mix, each primer at 300 nM, probe at 200 nM and template 
DNA.  
Reverse transcription for the quantification of HIV-1 RNA load in blood and seminal 
plasma was performed with the RevertAid reverse Transcriptase kit (Fermentas, 
Glen Burnie, MD) according to the manufacturer’s instructions. Reverse 
transcription was performed in 20µl reaction mixture containing 1X Reaction buffer, 
1 mM dNTPs, 20U of RNAse inhibitor, 2.5 µM random hexamers, 200 U of MMuLV 
Reverse Transcriptase and template RNA. Each reaction was performed for 5 min 
at 25°C, 60 min at 42°C and inactivation step for 10 min at 70°C using an 
Eppendorf Mastercycler instrument (Eppendorf, Hauppauge NY). A SYBR green 
real-time PCR assay was then used to quantify HIV-1 RNA load. The amplifications 
were conducted using a set of primers (forward primer: tgtgtgcccgtctgttgtgt; reverse 
primer: gagtcctgcgtcgagagagc) amplifying 100 base pair of a highly conserved 
region of HIV-1gag previously described for the quantification of HIV-1 load of 
different group M HIV-1 subtypes including subtype C [220]. 
Reference standard curves were generated using serially diluted plasmids 
containing the target genes or a commercially available quantitated viral DNA 
(Advanced Biotechnologies, Columbia, MD). Aliquots were prepared once by 
	  	   51	   	  
	  
dilution of DNA in distilled water and were stored at -20°C. Water and DNA 
extracted from HIV-1-uninfected and HHV-free cell line (MT4) were included for 
each of the amplifications as negative controls. Following activation of DNA 
polymerase at 95°C for 10 min, 40 cycles of amplification (denaturation step 95°C 
for 15 sec; annealing-extension step 60°C for 1 min) were performed with an ABI 
7500 Fast Real-Time PCR sequence detector (Applied Biosystems, Foster City, 
CA). For HIV-1, a dissociation profile was obtained by ramping from 60°C to 95°C. 
An accurate analysis of the melting temperature curve of the generated amplicons 
was conducted for all the amplifications to rule out any non-specific interference. 
Data were analyzed using sequence detection software (Applied Biosystems SDS 
v1.3.1). For purposes of statistical analysis samples with undetectable HIV-1 RNA 
or herpesvirus DNA were arbitrary considered to contain 3 copies/mL. 
2.3 Cytokine quantification 
Using a multiplex bead array we measured the levels of the following 21 cytokines: 
interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-7, IL-8 (CXCL8), IL-15, IL-16, macrophage 
inflammatory protein (MIP)-1α (CCL3), MIP-1β (CCL4), MIP-3α (CCL20), regulated 
on activation normally T-cell expressed and secreted (RANTES; CCL5), monocyte 
chemotactic protein-1 (MCP-1; CCL2), eotaxin (CCL11), interferon (IFN)-γ, 
monokine induced by IFN-γ (MIG; CXCL9), IFN-γ-inducible protein 10 (IP-10; 
CXCL10), stromal derived factor (SDF)-1β (CXCL12b), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), tumor necrosis factor (TNF)-α, and 
transforming growth factor (TGF)-β.  
2.3.1 Coupling of antibodies to beads 
Individual carboxylated polystyrene Luminex bead sets (Itachi Mirabio, Alameda, 
CA) were coupled to cytokine-specific capture monoclonal antibodies using a two-
step corbodiimide coupling procedure. 1 mL of beads at the concentration of 12.5 
beads/mL was transferred in a 1.5 mL protein low binding tube (Eppendorf, 
Hauppauge, NY) and centrifugated at 8000xg for 2 minutes. Pelletted beads were 
washed once with cell culture grade water by vortex and sonication for 30 seconds 
and then resuspended in 160 μL of 100 mM monobasic sodium phosphate 
(pH=6.2). Beads were activated fro 20 minutes at room temperature (RT) by 
addition of 20 μL of 50 mg/mL solution of EDC (1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride) (Thermo Fisher Scientific, 
Rockford, IL) in water and 20 μL of a freshly prepared 50 mg/mL solution of Sulfo-
NHS (N-hydroxysulfosuccinimide, Thermo Fisher Scientific) in water. Activated 
beads were washed twice with PBS (pH 7.4) and resuspended in 500 μL of PBS. 
200 μg of cytokine-specific capture antibody diluted in PBS were added to the bead 
suspension. After bringing total volume to 1 mL with PBS, beads were incubated 
for 2 hours by mixing by rotation at RT and overnight at 4 °C. Beads were washed 
twice with 500 μL of PBS-TBN (PBS, 0.1% BSA, 0.02% Tween-20, 0.05% Azide, 
pH 7.4) and resuspended in 500 μL of PBS-TBN. Beads were enumerated using 
an automated hemocytometer (Cellometer, Nexcelom Bioscience, Lawrence, MA) 
and presence of antibodies coupled to the bead surface was verified using an anti-
mouse IgG R-Phycoerythrin (RPE)-conjugated antibody (Invitrogen, Carlsbad, CA). 
Conjugated beads were kept at 4°C until use. All capture monoclonal antibodies 
were purchased from R&D (Minneapolis, MN).  
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2.3.2 Bead-based array assay 
Biotinylated polyclonal antibodies were used at twice the concentrations 
recommended for a classical ELISA (according to the manufacturer). All assay 
procedures were performed in assay buffer containing PBS supplemented with 
0.1% normal mouse serum (Gemini Bioproducts, West Sacramento, CA), 0.1% 
goat serum (Gemini Bioproducts), 0.05% TWEEN-20, and 20 mM Tris-HCl (pH 
7.4). The assays were run using 2000 beads of each bead set per well in a total 
volume of 50 μL. A total of 50 μL of each sample was added to the well and 
incubated overnight at 4°C in a Millipore Multiscreen plate (Millipore, Billerica, MA). 
The liquid was then aspirated using a Vacuum Manifold (Millipore), and the plates 
were washed twice with a solution of 0.05% TWEEN-20, and 20 mM Tris-HCl in 
PBS (pH 7.4). The beads were then resuspended in 50 μL of assay buffer 
containing biotinylated polyclonal antibodies specific for the measured cytokines for 
30 minutes at room temperature. The plates were washed twice with washing 
buffer using the vacuum manifold. The beads were resuspended in 100 μL of 
assay buffer containing RPE-conjugated streptavidin (Invitrogen) at the 
concentration of 8 μg/mL and incubated for 30 minutes at RT shaking. The plates 
were washed twice with washing buffer using the vacuum manifold and beads were 
resupsended in 100 μL of assay buffer. 
All detection byotinilated antibodies and recombinant human cytokines used as 
standards were purchased from R&D.  
The plates were read on a Luminex-100 platform. For each bead set of the 21 
tested, a minimum of 100 beads in a volume of 80 μL was recorded in the region-
specific gate. The median fluorescence intensity was recorded for each of these 
beads and was used for analysis with the Bio-Plex Manager software (version 5.0; 
Bio-Rad, Hercules, CA) using a 5P regression algorithm.  
Values that were below the lower limit of detection (LLD) were reported as the 
midpoint between zero and the LLD (LLDs in pg/mL: IL-1β: 4; IL-2: 12.1; IL-6 and 
IL-7: 4.7; CXCL8: 16.4; IL-15: 10.3; IL-16: 20.6; CCL3: 39.1; CCL20: 6.2; CCL5: 
10; CCL2: 25; CCL11: 7.5; IL-1α, GM-CSF, CCL4, IFN-γ, CXCL9, and CXCL10: 
3.4; TNF-α: 2.1; CXCL12b and TGF-β: 6.9). 
2.4 Human tissue culture 
2.4.1 Preparation of collagen sponge gels 
Explant culture medium (ECM) was prepared as follow: RPMI 1640 (Gibco Life 
Technologies, Grand Island, NY), 15% of fetal bovine serum (Gemini Bioproducts, 
West Sacramento, CA), 0.1 mM of MEM-nonessential amino acids (Gibco Life 
Technologies), 2.5 μg/mL fungizone (Gibco Life Technologies), 1 mM MEM–
sodium pyruvate (Gibco Life Technologies) and 50 μg/mL of gentamicin (Cellgro-
Mediatech, Manassas, VA).  
Collagen sponge gels 12-7 mm (adsorbable gelatin sponge; Pharmacia and 
Upjohn Company, distributed by Pfizer) were hydrated in ECM supplemented with 
timentin at the concentration of 0.3 mg/mL using a bent flat spatula to press the gel 
against the bottom of a petri dish. This process is critical to avoid that the presence 
of air will block the capillaries through which nutrients reach the tissue. For tonsillar 
tissue, rehydrated collagen sponge gels were cut in 4 equal pieces that were 
placed into a 6-well plate (1 piece into each well) containing 3 mL of ECM 
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supplemented with timentin per well. For cervico-vaginal tissue, gels were cut into 
6 equal pieces that were placed into a 12-well plate containing 1 ml of ECM 
supplemented with timentin per well.  
2.4.2 Dissection and ex vivo infection of human tissues with HIV-1 
To establish long-term tissue culture, it is critical to start the experiment with 
tissues in good condition, lacking blood clots and necrotic parts [210]. Tonsillar 
tissue was delivered within 5 hours post-surgery in saline solution without ice 
cooling during transportation. Cervico-vaginal, which is sturdier and less 
susceptible to deterioration than tonsillar tissue, was delivered after 24 hours post-
surgery, in ice-cold RPMI 1640.     
2.4.2.1 Lymphoid tissue 
Tonsils were dissected into big pieces using a 10-gauge blade scalpel and forceps. 
Cauterized tissue, the capsule surrounding the tissue, bloody, inflamed parts, and 
any parts containing tonsillolithes or necrotic (light brown-green color) were 
removed (Fig 2.1A). Tonsillar tissue was dissected into approximately 8 mm3 
blocks and placed on collagen sponge gels (9 blocks per piece) at the air-liquid 
interface (Fig 2.1B). For each experimental condition 18 or 27 blocks were used 
depending on the experiment. Blocks were maintained in culture overnight at 37°C, 
5% CO2, and high relative humidity (>83%).  
The day after, medium was changed using ECM supplemented with timentin. 
Tissue blocks were infected by application of 6.3 µL of HIV-1BaL or HIV-1LAI.04 
undiluted or 1:100 diluted in RPMI 1640, on top of each block and maintained at 
37°C, 5% CO2, and high relative humidity.  
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Figure 2.1 Preparation of tonsillar tissue for histoculture. (A) Black arrows point to 
the part of the tissue that should be discarded. (B) Tissue before and after being 
deposed on collagen sponge gel in a 6-well plate.    
(From Grivel & Margolis, 2009 [210]). 
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2.4.2.2 Cervico-vaginal tissue 
In the received cervical samples, the endocervix was recognized as the part with 
darker color and usually coated by thick mucus (Fig. 1.6). The mucosal epithelium 
and the underlying stroma of both the ectocervix and the endocervix were 
separated from the muscular tissue and dissected into approximately 8 mm3 blocks 
using a 23-gauge blade scalpel and forceps.  
For each experimental condition, 24 cervical blocks were transferred into two 1.5-
mL conical tubes (12 blocks per tube), each containing 0.35 mL of viral stock HIV-
1BaL. After 2 hours of incubation at 37 °C in a thermomixer at 300 rears per minute 
(rpm), tissue blocks were transferred into a 6-well plate and gently washed three 
times with 4 mL of PBS. Blocks were placed on top of a collagen sponge gel into a 
12-well plate (8 blocks/well). Blocks were maintained in culture at 37°C, 5% CO2, 
and high relative humidity (>83%). As control to discriminate productive HIV-1 
replication from virus absorption and subsequent release from the tissue, we 
infected cervico-vaginal blocks with HIV-1BaL in the presence of the HIV reverse 
transcriptase inhibitor Lamivudine, also known as 3TC, at the concentration of 10 
µM. Lamivudine 10 µM was maintained for all the length of tissue culture.  
2.4.2.3 Treatment with interleukin-7 
Recombinant human interleukin (IL)-7 (Peprotech, Rocky Hill, NJ) was added to 
culture medium at the concentration of 5 or 25 ng/mL and tonsillar and cervico-
vaginal tissue blocks were maintained in culture in the presence or in the absence 
of IL-7 for 6, 9, or 12 days (depending on the goal of the experiment). Tonsillar 
tissue blocks were treated with IL-7 immediately after cutting and incubated 
overnight with IL-7 before HIV-1 infection. IL-7 was added to the viral stock during 
infection of cervico-vaginal tissue blocks. Culture medium was sampled by pooling 
the medium from all 2 or 3 wells of same condition and thereafter medium was 
changed using ECM without timentin every third day after infection.  
2.5 Viruses 
To infect lymphoid and cervico-vaginal tissue block ex vivo we used 2 different 
prototypic HIV-1 variants: the CCR5-using virus HIV-1BaL, and the CXCR4-using 
virus HIV-1LAI.04. Both HIV-1BaL and HIV-1LAI.04 viral preparations were obtained 
from the Virology Quality Assurance Laboratory at Rush University (Chicago, IL). 
Viral stocks were obtained from the medium of peripheral blood mononuclear cell 
cultures inoculated with either HIV-1BaL or HIV-1LAI.04, originally received from the 
NIH AIDS Reagent Program. HIV-1 p24gag antigen concentrations were 49 ± 3 and 
53 ± 3 ng/mL for HIV-1BaL and HIV-1LAI.04 stock, respectively. Viral inocula were 
adjusted to obtain similar replication levels in lymphoid and cervico-vaginal tissue.  
2.6 Flow cytometry  
Tissue blocks were harvested and transferred into a 1.5 mL conical tube. Tonsillar 
and cervico-vaginal tissue blocks were respectively digested for 30 and 45 min with 
Liberase low Dispase concentration (Roche, Indianapolis, IN) at 8 µg/mL (final 
concentration) in 1 mL of RPMI1640 (Gibco Life Technologies) containing DNase I  
(Roche) at 100 µg/mL (final concentration) at 37 °C in a thermomixer at 900 rpm. 
After digestion, the cell suspension was removed from the tube and filtered with a 
prewet 100 µm cell-strainer (BD Bioscience, San Jose, CA) placed on top of a 50 
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mL tube containing 10 mL of PBS. Tissue blocks in the digestion tube were 
mechanically disrupted with a pestle and washed with PBS, and the cell 
suspension was transferred in the cell-strainer. Gel foam was disrupted with 
forceps and transferred in the cell strainer together with culture medium left after 
sampling. Cell suspension was centrifugated at 250xg for 5 min, and resuspended 
in 1 mL of PBS containing 2 µL of Live–Dead fixable blue fluorescent reactive dye 
reagent kit (Invitrogen) and incubated at RT for 20 min, in the dark. Cells were 
washed with 1 mL of staining buffer (PBS supplemented with 2% normal mouse 
serum (Gemini Bioproducts)). All washing steps were performed using 1 mL of 
staining buffer. To characterize tissue lymphocytes, cells were stained with the 
monoclonal antibodies anti-CD3 Qdot 655, anti-CD4 Qdot 605, and anti-CD8 
Pacific Blue (Invitrogen) in a final volume of 200 µL, at RT for 20 mins, in the dark. 
After surface staining, cells were washed and then permeabilized with a Fix & 
Perm kit according to manufacturer instructions (Invitrogen). Cells were stained 
with an anti-HIV-1 p24gag monoclonal antibody (KC57) conjugated with fluorescein 
isothiocyanate (FITC) (Beckman Coulter, Indianapolis IN), anti-Bcl-2 
phycoerythrine (PE) (BD Bioscience), and anti-APO2.7 PE-Cyanin5 (Beckman 
Coulter) in a final volume of 200 µL, at RT for 20 mins, in the dark. Cells were 
washed and then fixed with 200 µL of 2% paraformaldehyde solution in PBS at RT 
for 20 mins, in the dark. Cells were washed and resuspended in 200 µL of staining 
buffer. Data were acquired on an LSRII flow cytometer (BD Biosciences) equipped 
with 355-, 407-, 488-, 532-, and 638-nm laser lines using DIVA 6.1.2 software (BD 
Biosciences), and analyzed with the software FlowJo version 9.4.10 (Tree Star, 
Ashland, OR). We identified lymphocytes according to their light-scattering 
properties. We quantified cell depletion by weighting tonsillar blocks prior to digest 
and by adding 100 µL of AccuCheck counting beads (Invitrogen) to cell suspension 
before acquiring. At least 10000 events were acquired in the bead-corresponding 
gate.  
2.7 Dynamic immunofluorescent cytometric bead assay for HIV-
1 p24gag quantification  
We evaluated productive HIV-1 infection from measurements of HIV-1 p24gag 
antigen in medium of tonsillar and cervico-vaginal tissue cultures, using a dynamic 
immunofluorescent cytometric bead assay.  
Carboxylated magnetic Luminex beads region 42 (Itachi Mirabio) were coupled to a 
high-affinity anti-p24gag monoclonal antibody (ImmunoDiagnostics Inc, Woburn, 
MA) using a two-step corbodiimide coupling procedure (described in section 2.3.1). 
All assay procedures were performed in assay buffer containing PBS 
supplemented with 0.1% bovine serum albumin, 0.05% TWEEN-20, and 20 mM 
Tris-HCl (pH 7.4). The assays were performed using 2000 beads per well in a total 
volume of 50 μL. Culture medium samples were lysed by incubation with a Triton X 
100 solution 1% (final concentration) for 1 hour at 37 °C. 50 µL of lysed samples 
were added to the bead solution in a flat-bottom 96-well microplate (NUNC Thermo 
Scientific) and were incubated for 1 hour at RT shaking and at 4 °C overnight. The 
plates were washed twice with 200 µL of PBS supplemented with 0.05% TWEEN-
20 and 20 mM Tris-HCl (pH 7.4) using a microplate wash instrument (Bio-Plex Pro 
Wash Statio, Bio-Rad). 100 µL of the RD1 PE-labeled anti-HIV-1 p24gag KC57 
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antibody (Beckman Coulter) diluted in assay buffer to the concentration of 
0.5 µg/mL were added to the bead solution and incubated for 30 minutes at RT 
shaking. The plates were washed twice with 200 µL of washing buffer and beads 
were resuspended in 100 µL of assay buffer. p24gag standard (Alliance p24 Kit 
standard) were purchased from PerkinElmer (Waltham, MA). 
The plates were read on a Luminex-100 platform. A minimum of 100 beads in a 
volume of 80 μL was recorded in the region-specific gate. The median fluorescence 
intensity was recorded for each of these beads and was used for analysis with the 
Bio-Plex Manager software (version 5.0; Bio-Rad) using a 5P regression algorithm.  
2.8 Statistical analysis 
We compared continuous variables between groups using the Mann-Whitney test. 
The Kruskall-Wallis Test with the Dunn Multiple Comparison Test was used to test 
for differences among more than two independent groups. We compared 
categorical variables using Fisher`s Exact and and the chi-square test. We 
assessed linear association of continuous variables using the non-parametric 
Spearman`s rank correlation coefficient (ρ). McNemar's chi-squared test was used 
to determine whether the number of correlations differed by HIV-1 status. 
Multivariate manova analysis of the subsets of cytokines in blood and semen of 
HIV-1-infected and HIV-1-uninfected men that resulted in a measured value in all 
tested samples was performed to exclude a possible effect on the correlations by 
the cytokines that were below the lower limit of detection. 
To account for inter-tissue donor variability, we calculated the ratios of the values 
of HIV-1 p24gag concentrations in culture media, numbers and percentages of CD8− 
p24+ cells, percentages of CD8− APO2.7+ cells, and Bcl-2 MFI, between IL-7-
treated and IL-7-untreated donor-matched tissues. For CD4+ T cell depletion, we 
calculated the difference in the percentages of CD3+ CD8− cells between IL-7-
treated and IL-7-untreated donor-matched tissues. Statistical differences from 0 
were evaluated after natural logarithm (logn) transformation of the ratio or 
difference values using the One Sample t test. All hypothesis tests were two-tailed, 
and a p-value of  <0.05 defined statistical significance. 
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